<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:52:30Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3985721" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3985721</identifier><datestamp>2015-03-14</datestamp><setSpec>acssd</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article" xml:lang="EN">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Biochemistry</journal-id>
      <journal-id journal-id-type="iso-abbrev">Biochemistry</journal-id>
      <journal-id journal-id-type="publisher-id">bi</journal-id>
      <journal-id journal-id-type="coden">bichaw</journal-id>
      <journal-title-group>
        <journal-title>Biochemistry</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0006-2960</issn>
      <issn pub-type="epub">1520-4995</issn>
      <publisher>
        <publisher-name>American
Chemical Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3985721</article-id>
      <article-id pub-id-type="pmcid">PMC3985721</article-id>
      <article-id pub-id-type="pmc-uid">3985721</article-id>
      <article-id pub-id-type="pmid">24669844</article-id>
      <article-id pub-id-type="doi">10.1021/bi500129k</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Interfacial Residues Promote an Optimal Alignment
of the Catalytic Center in Human Soluble Guanylate Cyclase: Heterodimerization
Is Required but Not Sufficient for Activity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="ath1">
          <name>
            <surname>Seeger</surname>
            <given-names>Franziska</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">â </xref>
          <xref rid="aff3" ref-type="aff">Â§</xref>
        </contrib>
        <contrib contrib-type="author" id="ath2">
          <name>
            <surname>Quintyn</surname>
            <given-names>Royston</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">â¡</xref>
        </contrib>
        <contrib contrib-type="author" id="ath3">
          <name>
            <surname>Tanimoto</surname>
            <given-names>Akiko</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">â¡</xref>
        </contrib>
        <contrib contrib-type="author" id="ath4">
          <name>
            <surname>Williams</surname>
            <given-names>Gareth J.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">Â§</xref>
        </contrib>
        <contrib contrib-type="author" id="ath5">
          <name>
            <surname>Tainer</surname>
            <given-names>John A.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">Â§</xref>
          <xref rid="aff4" ref-type="aff">â¥</xref>
        </contrib>
        <contrib contrib-type="author" id="ath6">
          <name>
            <surname>Wysocki</surname>
            <given-names>Vicki
H.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">â¡</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="ath7">
          <name>
            <surname>Garcin</surname>
            <given-names>Elsa D.</given-names>
          </name>
          <xref rid="cor1" ref-type="other">*</xref>
          <xref rid="aff1" ref-type="aff">â </xref>
        </contrib>
        <aff id="aff1"><label>â </label><institution>University
of Maryland Baltimore County</institution>, Baltimore, Maryland 21250, <country>United States</country></aff>
        <aff id="aff2"><label>â¡</label><institution>The
Ohio State University</institution>, Columbus, Ohio 43210, <country>United States</country></aff>
        <aff id="aff3"><label>Â§</label><institution>Lawrence
Berkeley National Laboratory</institution>, Berkeley, California 94720, <country>United States</country></aff>
        <aff id="aff4"><label>â¥</label><institution>The
Scripps Research Institute</institution>, La
Jolla, California 92037, <country>United States</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>Department of Chemistry and Biochemistry,
University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore,
MD 21250. E-mail: <email>egarcin@umbc.edu</email>. Telephone: <phone>(410) 455-2512</phone>. Fax: <fax>(410) 455-2608</fax>.</corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>03</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>03</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>08</day>
        <month>04</month>
        <year>2014</year>
      </pub-date>
      <volume>53</volume>
      <issue>13</issue>
      <fpage>2153</fpage>
      <lpage>2165</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>01</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>12</day>
          <month>03</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2014 American Chemical
Society</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>American Chemical
Society</copyright-holder>
      </permissions>
      <abstract>
        <p content-type="toc-graphic">
          <graphic xlink:href="bi-2014-00129k_0009" id="ab-tgr1"/>
        </p>
        <p>Soluble guanylate cyclase (sGC) plays
a central role in the cardiovascular
system and is a drug target for the treatment of pulmonary hypertension.
While the three-dimensional structure of sGC is unknown, studies suggest
that binding of the regulatory domain to the catalytic domain maintains
sGC in an autoinhibited basal state. The activation signal, binding
of NO to heme, is thought to be transmitted via the regulatory and
dimerization domains to the cyclase domain and unleashes the full
catalytic potential of sGC. Consequently, isolated catalytic domains
should show catalytic turnover comparable to that of activated sGC.
Using X-ray crystallography, activity measurements, and native mass
spectrometry, we show unambiguously that human isolated catalytic
domains are much less active than basal sGC, while still forming heterodimers.
We identified key structural elements regulating the dimer interface
and propose a novel role for residues located in an interfacial flap
and a hydrogen bond network as key modulators of the orientation of
the catalytic subunits. We demonstrate that even in the absence of
the regulatory domain, additional sGC domains are required to guide
the appropriate conformation of the catalytic subunits associated
with high activity. Our data support a novel regulatory mechanism
whereby sGC activity is tuned by distinct domain interactions that
either promote or inhibit catalytic activity. These results further
our understanding of heterodimerization and activation of sGC and
open additional drug discovery routes for targeting the NOâsGCâcGMP
pathway via the design of small molecules that promote a productive
conformation of the catalytic subunits or disrupt inhibitory domain
interactions.</p>
      </abstract>
      <funding-group>
        <funding-statement>
          <funding-source>National Institutes of Health, United States</funding-source>
        </funding-statement>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>document-id-old-9</meta-name>
          <meta-value>bi500129k</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>document-id-new-14</meta-name>
          <meta-value>bi-2014-00129k</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>ccc-price</meta-name>
          <meta-value/>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes id="notes-1">
      <fn-group>
        <fn id="d31e189" fn-type="funding-statement">
          <p>This work was
supported in part by grants from the American Heart Association (10SDG2600345
to E.D.G. and 13PRE17000045 to F.S.), the National Institutes of Health
(R01GM039345 to J.A.T.), and the National Science Foundation (DBI0923551
to V.H.W.).</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <p id="sec1">The enzyme
soluble guanylate
cyclase (sGC) plays a key role in the cardiovascular system and is
a validated drug target for the treatment of cardiovascular diseases.<sup><xref ref-type="bibr" rid="ref1">1</xref>â<xref ref-type="bibr" rid="ref5">5</xref></sup> It catalyzes the formation of the cardioprotective signaling molecule
cyclic guanosine monophosphate (cGMP) from guanosine triphosphate
(GTP).<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Nitric oxide (NO) binds to the
N-terminal regulatory domain, thereby inducing the transition from
basal to activated sGC, resulting in an increased level of cGMP production.
Under conditions of oxidative stress, decreased NO bioavailability<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> and increased levels of oxidation of sGC both lead to impaired sGC
activation and decreased levels of cGMP production.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Additional physiological regulators of sGC are being discovered,
such as the thrombospondin-1/CD47 signaling pathway,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> that are capable of further decreasing sGC activity.<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup> Restoring healthy levels of cGMP in the diseased state thus requires
alternative ways to activate sGC. Understanding the molecular events
controlling sGC activity may lead to additional classes of cGMP-modulating
therapeutics. However, despite great progress in the field, sGC regulation
is largely enigmatic. With this goal in mind, we aim to characterize
structural changes that occur at the catalytic center during the activation
process.</p>
    <p>The sGC enzyme is a heterodimer of Î± and Î²
subunits<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> sharing a similar modular organization:
an HNOX
regulatory domain, an HNOXA domain and a coiled-coil (CC) domain involved
in dimerization, and a catalytic guanylate cyclase (GC) domain, from
the N- to C-terminus. Crystal structures of independent sGC domains
and homologues have been determined,<sup><xref ref-type="bibr" rid="ref13">13</xref>â<xref ref-type="bibr" rid="ref20">20</xref></sup> and recent low-resolution electron microscopy data suggest how these
domains might assemble in the full-length enzyme.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> However, the high-resolution three-dimensional structure
of full-length sGC is still missing. Both long-range domainâdomain
interactions and local short-range conformational changes were proposed
to account for sGC activation. Several studies point to the inhibitory
interaction of the Î²HNOX domain with the cyclase domain.<sup><xref ref-type="bibr" rid="ref22">22</xref>â<xref ref-type="bibr" rid="ref25">25</xref></sup> Furthermore, the Î±HNOX and Î±HNOXA domains were shown
to be located near the Î²HNOX domain to keep it in an inhibited
conformation that is released upon NO or YC-1 binding.<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> From these results, a collective model in which the N-terminal regulatory
domains autoinhibit sGC activity was developed. If this model is correct,
then isolated cyclase domains should display high levels of activity.</p>
    <p>Here we combined X-ray crystallography, activity measurements,
and native mass spectrometry analysis of the wild-type human heterodimeric
catalytic domains of sGC (hereafter termed Î±Î²GC) to characterize
the structural features that modulate the orientation of the catalytic
subunits leading to sGC activity and to propose a novel model for
sGC regulation.</p>
    <sec sec-type="methods" id="sec2">
      <title>Experimental Procedures</title>
      <sec sec-type="materials" id="sec2.1">
        <title>Materials</title>
        <p>All
chemicals were obtained from Sigma-Aldrich
and purification columns from GE Healthcare unless otherwise indicated.</p>
      </sec>
      <sec id="sec2.2">
        <title>Mutagenesis, Expression, and Purification of the Î±Î²GC
Heterodimer, Î±GC, and Î²GC</title>
        <p>Entry clones for human
Î±<sub>3</sub>GC GUCY1A3 (amino acids 466â690, GenBank
accession number JX420281) with an N-terminally His-tagged thioredoxin tag
in a pNH-TrxT vector and mutant Î²<sub>1</sub>GC GUCY1B3 (amino
acids 407â619, GenBank accession number JX420282) with
a C-terminally His-tagged Flag tag in a pNIC-CTHF vector were kind
gifts of Dr. Allerston (Structural Genomics Consortium). The Î²GC
G476C/C541S double mutant was changed back to the wild type using
standard site-directed mutagenesis (Stratagene) with the following
primer pairs: forward primer (5â²-cgttactgcctgttcggc-3â²)
and reverse primer (5â²-gccgaacaggcagtaacg-3â²)
for C476G and forward primer (5â²-cgaaactgttggcgataagtatatga-3â²)
and reverse primer (5â²-tcatatacttatcgccaacagtttcg-3â²)
for S541C.</p>
        <p>We also designed a shorter construct for Î±GC,
named Î±GC661 (residues 466â661) by inserting a stop codon
at position 662 by site-directed mutagenesis with the following primer
pairs: forward primer (5â²-gatgcgtatcagtagtgaaccaactcaaaa-3â²)
and reverse primer (5â²-ttttgagttggttcactactgatacgcatc-3â²).
All mutations were confirmed by DNA sequencing (Genewiz).</p>
        <p>Each
catalytic subunit was independently co-expressed with the
GroEL-ES chaperone system from a pACYC-derived plasmid (Takara Inc.)
in <italic>Escherichia coli</italic> BL21(DE3) cells (Life Technologies).
Cells were cultured overnight at 37 Â°C. Protein expression was
induced with 1 mM IPTG and <sc>l</sc>-arabinose (2 g/L) when OD<sub>600</sub> reached 1. Cells were grown for 20 h at 15 Â°C, pelleted,
and frozen at â80 Â°C until they were used. To purify the
Î±Î²GC heterodimer, cell pellets from each subunit were
mixed and lysed in buffer A [50 mM sodium phosphate (pH 7.4), 0.5
M NaCl, 30 mM imidazole, 0.1% (v/v) Tween 20, 0.1 mg/mL DNaseI, 0.5
mg/mL lysozyme, and protease inhibitor cocktail (Roche)] via sonication.
The first chromatography step was a nickel HisTrap affinity column,
and Î±GC and Î²GC co-eluted with a 15 to 100% gradient of
buffer B [50 mM sodium phosphate (pH 7.4), 0.5 M NaCl, and 0.3 M imidazole].
Both proteins were cleaved overnight [in 20 mM Tris-HCl (pH 8.0),
0.15 M NaCl, and 5% glycerol] using a His-tagged tobacco etch virus
(TEV) protease yielding Î±GC(466â690) and Î²GC(407â626).
For Î²GC, the seven extra C-terminal amino acids are part of
the linker for TEV cleavage of the C-terminal His-Flag tag. A second
Ni affinity step was performed to remove the cleaved tags and the
TEV protease. The proteins were further purified using a HiTrap Q
HP anion exchange column and Superdex 200 or Superdex 75 gel filtration
in a final buffer consisting of 20 mM Hepes (pH 7.5) and 0.15 M NaCl.
The protein was aliquoted, flash-frozen in liquid nitrogen, and stored
at â80 Â°C. The same protocol was used to purify all catalytic
constructs. The final yields are 3.5 mg of Î±GC, 0.75 mg of Î²GC,
0.25â1 mg of copurified Î±Î²GC, 0.8 mg of Î±GC661,
and 0.5â0.8 mg of copurified Î±GC661Î²GC per liter
of cell culture.</p>
      </sec>
      <sec id="sec2.3">
        <title>Crystallization, Data Collection, and Refinement</title>
        <p>Crystals
of wild-type Î±Î²GC catalytic domains were grown at 20 Â°C
using a vapor diffusion sitting drop setup containing 0.2 Î¼L
of 14 mg/mL Î±Î²GC with 0.2 Î¼L of a reservoir solution
composed of 20% (w/v) PEG3350, 50 mM HEPES (pH 7.0), and 1% Tryptone.
The drops were set up using an ArtRobbins Phoenix crystallization
robot. Before data collection, the crystal was cryo-protected in mother
liquor supplemented with 20% (v/v) ethylene glycol and flash-frozen
in the nitrogen cryo-stream. X-ray diffraction data were collected
on beamline 8.3.1 at the Advanced Light Source at Lawrence Berkeley
National Laboratory. Data processing and reduction were conducted
with MOSFLM.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Phasing by molecular replacement
was conducted with PHASER<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> using the mutant
Î±Î²GC structure [Protein Data Bank (PDB) entry 3UVJ] as a starting model.
The final model was obtained with iterative cycles of refinement with
PHENIX<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and rebuilding with COOT.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> The final model and structure factors were deposited
in the PDB (entry 4NI2).</p>
      </sec>
      <sec id="sec2.4">
        <title>Activity Assay</title>
        <p>The cyclase activity reaction was performed
using â¼5 Î¼M full-length sGC (based on the absorbance
at 431 nm) and â¼10 Î¼M catalytic constructs (based on
the absorbance at 280 nm). The reaction assay was conducted in 40
mM HEPES (pH 7.4), 0.5 mM dithiothreitol, 0.3 mM 3-isobutyl-1-methylxanthine,
1 mM GTP, and 3 mM MgCl<sub>2</sub> or MnCl<sub>2</sub>. The reaction
mixture was incubated at 15 Â°C for 20 min and the reaction stopped
with the addition of EDTA (final concentration of 10 mM). The reaction
mixture was stored at â80 Â°C until cGMP was quantified
using a cGMP enzyme immunoassay kit (R&amp;D) following the manufacturerâs
protocol. Activity was measured in duplicate, and the experiments
were repeated three times to ensure reproducibility.</p>
      </sec>
      <sec id="sec2.5">
        <title>Multiangle
Light Scattering</title>
        <p>The KW 403 gel filtration
column was equilibrated with buffer A [50 mM Tris-HCl (pH 8.0), 0.15
M NaCl, 5% glycerol, 1 mM MgCl<sub>2</sub>, and 1 mM TCEP]. Bovine
serum albumin was used as a reference. We injected 50 Î¼L of
Î±Î²GC at 30 Î¼M.</p>
      </sec>
      <sec id="sec2.6">
        <title>Mass Spectrometry (MS)</title>
        <p>The protein samples were buffer
exchanged into 0.1 M ammonium acetate (AA) buffer (pH 7.4) using either
size-exclusion chromatography spin columns (Bio-Rad) or Amicon Ultra-4
centrifugal filter units (EMD Millipore). Subsequently, the concentrations
of the buffer-exchanged proteins were calculated by measuring the <italic>A</italic><sub>280</sub>, and a solution of 0.1 M triethylammonium
acetate (TEAA) was added to the protein samples in a 1:4 (TEAA:AA)
ratio to produce charge-reduced catalytic dimers, unless otherwise
stated. In the <italic>K</italic><sub>D</sub> analysis of the catalytic
dimers, various protein concentrations were obtained by serial dilution
starting from the stock solution of the buffer-exchanged protein sample.
For all other mass spectrometry analyses, the concentration of catalytic
dimers used was 10 Î¼M, unless otherwise stated.</p>
        <p>Nano-electrospray
ionization mass spectrometry (nano-ESI/MS) analysis was conducted
by utilizing a modified Quadrupole Ion Mobility Time of Flight (Q-IM-TOF)
instrument (Synapt G2, Waters Corp., Manchester, U.K.) with a customized
surface-induced dissociation (SID) device installed before the IM
chamber as previously described.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> All
experiments were conducted using a nanoelectrospray source, using
a capillary voltage of 1.0â1.5 kV and a cone voltage of 50â75
V. No heating was applied to the cone. Nano-ESI glass capillary and
surface preparation procedures can be found elsewhere.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> The following instrumental conditions were used:
5 mbar for the source/backing pressure, 2 mbar for the nitrogen gas
pressure in the IM cell, rate of 120 mL/min for the flow of gas into
the helium cell, â¼6 Ã 10<sup>â7</sup> mbar in the
TOF analyzer, and a wave velocity and a height of 300 ms<sup>â1</sup> and 20 V, respectively, for IM experiments. Nano-ESI/MS is a gentle
method of ionization in which salts and solvent are often retained,
giving <italic>m</italic>/<italic>z</italic> values higher than those
calculated from sequence, especially for oligomers. This problem is
sometimes eliminated in nano-ESIâMS/MS measurements of fragments,
if the MS/MS approach unfolds the monomers causing a loss of salts,
solvents, and ligands.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3">
      <title>Results</title>
      <sec id="sec3.1">
        <title>Overall Structure of Wild-Type
Human Heterodimeric Î±Î²GC
and Comparison with Mutant Heterodimeric Î±Î²GC</title>
        <p>To identify the structural determinants for sGC catalytic activity,
we determined the X-ray structure of the wild-type heterodimeric Î±Î²GC
catalytic domains of human sGC in the apo form at 1.9 Ã resolution
(Figure <xref rid="fig1" ref-type="fig">1</xref>). The final model shows good statistics
with <italic>R</italic><sub>work</sub> and <italic>R</italic><sub>free</sub> values of 0.159 and 0.198, respectively, and 98.2% of
the residues in the allowed regions of the Ramachandran plot (Table <xref rid="tbl1" ref-type="other">1</xref>). The model comprises one heterodimer per asymmetric
unit and contains Î±GC residues 471â662, Î²GC residues
411â608, 342 water molecules, and six ethylene glycol molecules.
Residues at the N- and C-termini of Î±GC (466â470 and
663â690, respectively) and Î²GC (407â410 and 609â626,
respectively) were not visible in the electron density and were not
included in the final model. To rule out the possibility that these
proteins may be proteolyzed or degraded and to unambiguously determine
the masses of the purified proteins, we performed nano-ESI/MS analysis
on the Î±GC and Î²GC proteins purified individually or copurified
(Table <xref rid="tbl2" ref-type="other">2</xref>, <xref rid="notes-2" ref-type="notes">Supporting Information</xref>, and Figure S1 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). We confirmed that we crystallized heterodimeric Î±Î²GC
with a truncated Î±GC(466â662) subunit.</p>
        <fig id="fig1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Overall structure of
heterodimeric wild-type Î±Î²GC catalytic
domains that resembles the Chinese yin-yang symbol with both subunits
arranged in a head-to-tail conformation. (A and B) Ventral face of
the heterodimer as a cartoon (A) and a solvent accessible surface
representation (B). The deep extended substrate groove (shown by the
oval in panel B) bisects the ventral face, which contains the C-termini
of both subunits (denoted with C). The Î±GC subunit is colored
blue, and the Î²GC subunit is colored orange. The substrate binding
regions of Î±GC (residues 523â534) and Î²GC (residues
470â480) adopt an extended conformation in the absence of substrate
and metals (arrows). (C and D) The dorsal face of the heterodimer
as a cartoon (C) and a solvent accessible surface representation (D)
is flatter than the ventral face and contains the N-termini of both
subunits (denoted with N).</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0002" id="gr1" position="float"/>
        </fig>
        <table-wrap id="tbl1" position="float">
          <label>Table 1</label>
          <caption>
            <title>X-ray Data Collection and Refinement
Statistics</title>
          </caption>
          <table frame="hsides" rules="groups" border="0">
            <colgroup>
              <col align="left"/>
              <col align="left"/>
            </colgroup>
            <tbody>
              <tr>
                <td colspan="2" style="border:none;" align="center">Data Collection<xref rid="t1fn4" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">space group</td>
                <td style="border:none;" align="left"><italic>P</italic>212121</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">wavelength (Ã)</td>
                <td style="border:none;" align="left">1.116</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">resolution (Ã)</td>
                <td style="border:none;" align="left">69.7â1.9 (2.0â1.9)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">unit cell parameters (Ã)</td>
                <td style="border:none;" align="left"><italic>a</italic>Â =Â 49.5, <italic>b</italic>Â =Â 55.8, <italic>c</italic>Â =Â 139.4</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">no. of measurements</td>
                <td style="border:none;" align="left">240390Â (31623)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">no. of unique reflections</td>
                <td style="border:none;" align="left">31270Â (4438)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">redundancy</td>
                <td style="border:none;" align="left">7.7Â (7.1)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">completeness (%)</td>
                <td style="border:none;" align="left">99.8Â (98.7)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">â¨<italic>I</italic>/Ï(<italic>I</italic>)â©</td>
                <td style="border:none;" align="left">14.2Â (2.6)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left"><italic>R</italic><sub>merge</sub> (%)<xref rid="t1fn1" ref-type="table-fn">a</xref></td>
                <td style="border:none;" align="left">8.6Â (68)</td>
              </tr>
              <tr>
                <td colspan="2" style="border:none;" align="center">Refinement<xref rid="t1fn4" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">resolution range (Ã)</td>
                <td style="border:none;" align="left">69.7â1.9 (1.96â1.90)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">no. of protein atoms</td>
                <td style="border:none;" align="left">2964</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">no. of water atoms</td>
                <td style="border:none;" align="left">342</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">no. of heteroatoms</td>
                <td style="border:none;" align="left">30</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">rmsd of bond lengths (Ã)</td>
                <td style="border:none;" align="left">0.012</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">rmsd of bond angles (deg)</td>
                <td style="border:none;" align="left">1.3</td>
              </tr>
              <tr>
                <td style="border:none;" align="left"><italic>R</italic><sub>work</sub> (%)<xref rid="t1fn2" ref-type="table-fn">b</xref></td>
                <td style="border:none;" align="left">15.9Â (23.8)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left"><italic>R</italic><sub>free</sub> (%)<xref rid="t1fn3" ref-type="table-fn">c</xref></td>
                <td style="border:none;" align="left">19.8Â (26.8)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Ramachandran plot (%)</td>
                <td style="border:none;" align="left">Â </td>
              </tr>
              <tr>
                <td style="padding-left: 2em;" align="left">favored</td>
                <td style="border:none;" align="left">98.2</td>
              </tr>
              <tr>
                <td style="padding-left: 2em;" align="left">allowed</td>
                <td style="border:none;" align="left">0.8</td>
              </tr>
              <tr>
                <td style="padding-left: 2em;" align="left">generous</td>
                <td style="border:none;" align="left">0.0</td>
              </tr>
              <tr>
                <td style="padding-left: 2em;" align="left">disallowed</td>
                <td style="border:none;" align="left">0.0</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="t1fn1">
              <label>a</label>
              <p><italic>R</italic><sub>merge</sub> = â<sub><italic>h</italic></sub>â<sub><italic>i</italic></sub>|<italic>I</italic>(<italic>h</italic>,<italic>i</italic>)
â â¨<italic>I</italic>(<italic>h</italic>)â©|/â<sub><italic>h</italic></sub>â<sub><italic>i</italic></sub><italic>I</italic>(<italic>h</italic>,<italic>i</italic>), where <italic>I</italic>(<italic>h</italic>,<italic>i</italic>) is the intensity
of the <italic>i</italic>th observation of reflection <italic>h</italic> and â¨<italic>I</italic>(<italic>h</italic>)â© is the
average intensity of redundant measurements of reflection <italic>h</italic>.</p>
            </fn>
            <fn id="t1fn2">
              <label>b</label>
              <p><italic>R</italic><sub>work</sub> = â<sub><italic>h</italic></sub>||<italic>F</italic><sub>obs</sub>| â |<italic>F</italic><sub>calc</sub>||/â<sub><italic>h</italic></sub>|<italic>F</italic><sub>obs</sub>|.</p>
            </fn>
            <fn id="t1fn3">
              <label>c</label>
              <p><italic>R</italic><sub>free</sub> = â<sub><italic>h</italic></sub>||<italic>F</italic><sub>obs</sub>| â |<italic>F</italic><sub>calc</sub>||/â<sub><italic>h</italic></sub>|<italic>F</italic><sub>obs</sub>| for 5%
of the reserved reflections.</p>
            </fn>
            <fn id="t1fn4">
              <label>d</label>
              <p>Values in parentheses apply to the
highest-resolution shell.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="tbl2" position="float">
          <label>Table 2</label>
          <caption>
            <title>Comparison of Calculated and Experimental
Molecular Masses for the Different sGC Constructs Determined by Nano-ESI/MS
and Nano-ESI/MS/MS</title>
          </caption>
          <table frame="hsides" rules="groups" border="0">
            <colgroup>
              <col align="left"/>
              <col align="char" char="."/>
              <col align="char" char="."/>
              <col align="left"/>
            </colgroup>
            <thead>
              <tr>
                <th style="border:none;" align="center">construct</th>
                <th style="border:none;" align="center" char=".">calculated mass (Da)<xref rid="t2fn1" ref-type="table-fn">a</xref></th>
                <th style="border:none;" align="center" char=".">calculated mass (Da)<xref rid="t2fn2" ref-type="table-fn">b</xref></th>
                <th style="border:none;" align="center">experimental mass (Da)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td style="border:none;" align="left">Î±GC(466â690) (monomer)</td>
                <td style="border:none;" align="char" char=".">24671.2</td>
                <td style="border:none;" align="char" char=".">24687.5</td>
                <td style="border:none;" align="left">24740.8Â Â±Â 17.9 (10Â Î¼M)<xref rid="t2fn5" ref-type="table-fn">e</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î±GC(466â661) (monomer)<xref rid="t2fn4" ref-type="table-fn">c</xref></td>
                <td style="border:none;" align="char" char=".">21621.7</td>
                <td style="border:none;" align="char" char=".">21636.1</td>
                <td style="border:none;" align="left">21642.9Â Â±Â 18.3 (10Â Î¼M)<xref rid="t2fn5" ref-type="table-fn">e</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î±GC(466â690) (dimer)</td>
                <td style="border:none;" align="char" char=".">49342.4</td>
                <td style="border:none;" align="char" char=".">49375</td>
                <td style="border:none;" align="left">49489Â Â±Â 20.3 (10Â Î¼M)<xref rid="t2fn5" ref-type="table-fn">e</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î±GC(466â662) (dimer)<xref rid="t2fn3" ref-type="table-fn">d</xref></td>
                <td style="border:none;" align="char" char=".">43499.6</td>
                <td style="border:none;" align="char" char=".">43528.6</td>
                <td style="border:none;" align="left">43500.1Â Â±Â 55.4 (10Â Î¼M)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î±GC(466â661) (dimer)</td>
                <td style="border:none;" align="char" char=".">43243.4</td>
                <td style="border:none;" align="char" char=".">43272.2</td>
                <td style="border:none;" align="left">43403.1Â Â±Â 5.5 (10Â Î¼M)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î²GC(407â626) (monomer)</td>
                <td style="border:none;" align="char" char=".">24769.2</td>
                <td style="border:none;" align="char" char=".">24785.2</td>
                <td style="border:none;" align="left">24820.5Â Â±Â 47.8 (10Â Î¼M)<xref rid="t2fn5" ref-type="table-fn">e</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î²GC(407â626) (dimer)</td>
                <td style="border:none;" align="char" char=".">49538.4</td>
                <td style="border:none;" align="char" char=".">49570.4</td>
                <td style="border:none;" align="left">49636.7Â Â±Â 36.6 (10Â Î¼M)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î²GC(407â626) (tetramer)</td>
                <td style="border:none;" align="char" char=".">99076.8</td>
                <td style="border:none;" align="char" char=".">99140.8</td>
                <td style="border:none;" align="left">99929.9Â Â±Â 68.7 (10Â Î¼M)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î±Î²GC <break/> (heterodimer)</td>
                <td style="border:none;" align="char" char=".">49440.4</td>
                <td style="border:none;" align="char" char=".">49472.7</td>
                <td style="border:none;" align="left">49660.2Â Â±Â 38.7 (10Â Î¼M)</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">Î±GC661Î²GC (heterodimer)<xref rid="t2fn4" ref-type="table-fn">c</xref></td>
                <td style="border:none;" align="char" char=".">46390.9</td>
                <td style="border:none;" align="char" char=".">46421.3</td>
                <td style="border:none;" align="left">46449.5Â Â±Â 20.2 (10Â Î¼M)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="t2fn1">
              <label>a</label>
              <p>Monoisotopic masses
were calculated
from amino acid sequences with PeptideMass<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> from the Expasy Web site.</p>
            </fn>
            <fn id="t2fn2">
              <label>b</label>
              <p>Average masses were calculated from
amino acid sequences with PeptideMass<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> from the Expasy Web site.</p>
            </fn>
            <fn id="t2fn4">
              <label>c</label>
              <p>Species obtained by introducing
a stop codon at position 662 in the Î±GC(466â690) construct.</p>
            </fn>
            <fn id="t2fn3">
              <label>d</label>
              <p>Species obtained by cleavage
of
Î±GC(466â690) at the N- and C-terminal TEV cleavage sites.</p>
            </fn>
            <fn id="t2fn5">
              <label>e</label>
              <p>Measured mass obtained from
nano-ESI/MS/MS
at a SID voltage of 100 V.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The structure of heterodimeric Î±Î²GC resembles the Chinese
yin-yang symbol with the two subunits arranged in a head-to-tail conformation
(Figures <xref rid="fig1" ref-type="fig">1</xref>A,C). The catalytic domains were
crystallized without metal or substrate. Accordingly, the structure
reveals an inactive heterodimer conformation compared to that of active
adenylate cyclase.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> This is evidenced
both by the relative orientation of the two subunits leading to an
open active site and by the extended loop conformation of the core
regions containing the catalytic residues (Figure <xref rid="fig1" ref-type="fig">1</xref>A).</p>
        <p>We superimposed our structure on that of the mutant
heterodimeric
human Î±Î²GC containing an engineered disulfide bridge (Î±GC
C595âC476 Î²GC) at the dimer interface.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> Aside from the mutations (G476C and C541A), the two structures
are very similar, with an rmsd of 0.52 Ã for 397 amino acids,
but present subtle differences at the dimer interface (Movie S1 of
the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and in surface-exposed
regions (a detailed description of similarities and differences is
presented in the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). As a result, the Î±GC subunit and the Î²GC subunit present
a slightly different orientation relative to each other in our structure.
Overall, the Î±GC and Î²GC subunits are rotated by â¼3Â°
in the structure of the wild-type catalytic domains compared to the
mutant structure. While these differences may seem subtle, similar
conformational changes are observed in related adenylate cyclase between
the inactive and active structures, in which one of the subunit rotates
by 7Â° and secondary structure elements shift by 1â2 Ã.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> This example illustrates how small structural
changes at the dimer interface in this protein family have profound
effects on catalytic activity. In comparison to the structure of the
mutant catalytic domains of sGC, our structure reveals an Î±GCâÎ²GC
interface with high plasticity that is necessary for sGC activity.
Regardless, our structure is the closest to that of the catalytic
domains in full-length sGC, as it is heterodimeric and devoid of mutations.
As such, it represents an excellent starting model for the docking
of small molecules that either inhibit or activate sGC.</p>
      </sec>
      <sec id="sec3.2">
        <title>Amino Acid
Sequence Conservation Suggests Docking Sites for
Other sGC Domains and Key Interfaces for Activation of sGC</title>
        <p>To identify conserved regions in the catalytic heterodimer, we performed
multiple-sequence alignments for both the Î±GC and Î²GC
subunits (<xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and mapped
the sequence identity percentage of each residue onto the Î±Î²GC
structure (Figure <xref rid="fig2" ref-type="fig">2</xref>). The regions with the
highest degrees of sequence conservation are located in three regions
of the heterodimer: (i) the substrate channel on the ventral face
of the Î±Î²GC heterodimer (94% identical sequence), (ii)
the C-terminal subdomain of Î±GC present on the ventral face
of the heterodimer (78% identical sequence), and (iii) the dorsal
face of the heterodimer (94% identical sequence). While the substrate
channel is expected to be mainly invariant, the high level of sequence
conservation of the Î±GC C-terminal domain (residues 616â662)
is surprising and suggests that this domain may play an important
role in the assembly and/or regulation of sGC. This hypothesis is
supported by recent studies showing that the Î²HNOXâHNOXA
domains directly interact with the C-terminal domain of Î±GC<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> and could modulate the conformation of the active site. Interestingly,
mutation of solvent-exposed residue Î±GC Arg624 in that domain
to Ala leads to a dramatic increase in full-length sGC activity.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> It is tempting to speculate that this residue
plays a key role in domainâdomain interaction with the N-terminal
regulatory domains. Importantly, this region of the catalytic subunit
could be targeted for the rational design of small molecules or protein
therapeutics disrupting the inhibitory interactions between the regulatory
and catalytic domains.</p>
        <fig id="fig2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Map of the high levels of sequence conservation on the
ventral
face substrate channel and the Î±GC C-terminal domain and the
heterodimer cleft on the dorsal face of the Î±Î²GC structure.
We aligned &gt;20 sequences of eukaryotic Î±GC and Î²GC
domains
(<xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and mapped the
level of amino acid sequence conservation onto the Î±Î²GC
crystal structure, colored from blue (0% identical) to red (100% identical).
C-Termini of both subunits are marked with C, and N-termini are marked
with N. (A) The highly conserved substrate channel on the ventral
face is marked with an arrow. The C-terminal subdomain of Î±GC
is moderately to strongly conserved (orange to red) as indicated by
an oval. (B) The dimer interface region close to the N-termini of
both subunits on the dorsal face is largely invariant.</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0003" id="gr2" position="float"/>
        </fig>
        <p>Second, the highly conserved region of the dorsal
face of Î±Î²GC
serves as the point of contact with the preceding Î±Î²CC
dimerization domain, where it could modulate the interface between
the Î±GC and Î²GC subunits. There is no crystal structure
for heterodimeric Î±Î²CC, but recent studies unambiguously
demonstrated a parallel orientation of the CC domains in sGC.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> In this arrangement, both C-termini of Î±Î²CC would be
able to connect with the N-termini of the Î±Î²GC heterodimer
separated by â¼28 Ã on the dorsal face of the heterodimer
and located in the region with the highest level of sequence conservation.
This position of Î±Î²CC is consistent with recent mass spectrometry<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> and FRET data.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> This
model is also coherent with the CC domain acting as a platform on
which all the sGC domains assemble in full-length sGC.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> The fact that the entire region surrounding
the N-termini of the Î±Î²GC heterodimer is highly conserved
in the sGC family points to more than simply an anchoring area for
the preceding CC domain. Instead, we propose that the interface between
the cyclase and the CC domains is essential for catalysis and that
the CC promotes an optimal conformation of the catalytic subunits
for activity.</p>
      </sec>
      <sec id="sec3.3">
        <title>Structural Determinants for Heterodimerization
of the Catalytic
Subunits</title>
        <p>Our crystallization trials with copurified wild-type
Î±Î²GC protein yielded mostly homodimeric Î²<sub>1</sub>Î²<sub>2</sub>GC crystals (98%) and some heterodimeric Î±Î²GC
crystals (2%). Others also noted difficulties in obtaining heterodimer
crystals of the wild-type catalytic domains and engineered a non-natural
disulfide bridge at the interface to favor heterodimerization.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> This suggests that Î²<sub>1</sub>Î²<sub>2</sub>GC has a stronger propensity to crystallize and/or that the
Î²<sub>1</sub>Î²<sub>2</sub>GC interface is stronger. To
address the first point, we performed native mass spectrometry and
crystal packing analysis (<xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and showed that, in our case, TEV cleavage at the N-terminal and
C-terminal sites in Î±GC yielded a minor population of Î±GC662Î²GC
heterodimers that were subsequently crystallized, thus explaining
our low success in crystallizing Î±Î²GC heterodimers (<xref rid="notes-2" ref-type="notes">Supporting Information</xref>). Second, to identify
the structural determinants promoting heterodimerization of the catalytic
subunits, we compared the heterodimeric Î±Î²GC structure
with the homodimeric Î²<sub>1</sub>Î²<sub>2</sub>GC structure
(PDB entry 2WZ1) and analyzed both dimeric interfaces (<xref rid="notes-2" ref-type="notes">Supporting
Information</xref>). The structural superposition shows that the Î²<sub>2</sub>GC subunit of the homodimer and the Î²GC subunit of the
heterodimer overlay closely, while the Î²<sub>1</sub>GC subunit
of the homodimer and the Î±GC subunit of the heterodimer present
distinct orientations (Figure <xref rid="fig3" ref-type="fig">3</xref>A). In the heterodimer,
Î±GC is rotated â¼13Â° compared to Î²<sub>1</sub>GC in the homodimer, resulting in a different dimer interface. Both
the heterodimeric and homodimeric interfaces contain a large number
of hydrophobic interactions stabilizing the dimer core formed by both
subunits and lining the substrate-binding site (Table S1 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref> and Figure <xref rid="fig3" ref-type="fig">3</xref>C,D). In addition, both interfaces contain several polar interactions
between surface flexible structural elements (Figure <xref rid="fig3" ref-type="fig">3</xref>E,F).</p>
        <fig id="fig3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Structural determinants of catalytic domain dimerization.
(A and
B) Homodimeric Î²<sub>1</sub>Î²<sub>2</sub>GC (PDB entry 2WZ1) is colored light
green (Î²<sub>1</sub>GC) and dark green (Î²<sub>2</sub>GC).
The Î±Î²GC heterodimer is colored blue (Î±GC) and orange
(Î²GC). The ventral view (A) shows that Î²GC and Î²<sub>2</sub>GC subunits superimpose well, while Î±GC adopts a conformation
different from that of Î²<sub>1</sub>GC in the heterodimer and
homodimer, respectively. The dorsal view (B) shows the double flap-wrap
conformation of the homodimer flaps (light and dark green cartoon).
In the heterodimer depicted as a semitransparent solvent accessible
surface, only the Î²GC flap (orange cartoon) wraps on the Î±GC
subunit while the Î±GC flap (blue cartoon) is flipped out. (C
and D) The core of the heterodimeric interface is formed by numerous
hydrophobic interactions between residues from the Î²GC subunit
(orange) and the Î±GC subunit (blue), depicted as sticks. (E
and F) Polar interactions (hydrogen bonds and salt bridges) also contribute
to the heterodimeric interface. Residues from Î²GC (orange) and
Î±GC (blue) participating in these interactions are shown as
sticks.</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0004" id="gr3" position="float"/>
        </fig>
        <p>Despite the resemblance between
the two dimeric interfaces, one
major difference between the two structures is the conformation of
the Î²-hairpins of residues 532â539 in Î²<sub>1</sub>GC and 587â593 in Î±GC. We will herein refer to these
hairpins as âflapsâ. In the symmetrical homodimer, both
flapsâone contributed by each Î²GC subunitâparticipate
in the dimer interface by wrapping securely onto the Î±2 helix
on the partner subunit, in a âdouble flap-wrapâ conformation
(Figure <xref rid="fig3" ref-type="fig">3</xref>B). Residues from both flaps contribute
one salt bridge and ten of the thirteen polar interactions that stabilize
the homodimer. In the heterodimer, residues from the Î²<sub>1</sub>GC flap contribute three of the nine hydrogen bonds that stabilize
the dimer (Table S1 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>), while the Î±<sub>1</sub>GC flap is swung away and makes no
interaction with the Î²GC subunit (Figure <xref rid="fig3" ref-type="fig">3</xref>B). This suggests a different role of the flaps in the homodimer
and the heterodimer. We further performed a structural comparison
of all guanylate cyclase and adenylate cyclase catalytic domain structures
(<xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and proposed that
these surface-exposed structural flaps not only are involved in regulating
the relative orientations of the subunits in various dimers but also
may be important in modulating interactions with other domains or
proteins. For sGC, our results indicate a key role of the interfacial
flaps in stabilizing different dimer interfaces and suggest that the
flaps may also be important for the proper orientation of the catalytic
subunits in full-length sGC (see below).</p>
      </sec>
      <sec id="sec3.4">
        <title>Residues in the Interfacial
Flap and Hydrogen Bond Network Play
Key Roles in Modulating the Dimer Interface</title>
        <p>To begin to understand
the mechanisms involved in modulating sGC activity, we mapped sGC
residues that have been shown to significantly impact activity and
activation on our structure of the inactive heterodimer (Figures <xref rid="fig4" ref-type="fig">4</xref>A,B) and our model for the active heterodimer (Figures <xref rid="fig4" ref-type="fig">4</xref>C,D). These residues fall in two areas of the dimer
interface. (a) The first includes residues located in the flap or
in the region interacting with the flap on the partner subunit. In
full-length sGC, the Met537Asn mutation in Î²GC leads to increased
constitutive activity and a very strong response to NO and/or YC-1
activators.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> Met537 is located on the
Î²GC flap, and its position is not expected to change drastically
between the inactive and active conformation. However, reorientation
of Î±GC in the active heterodimer leads to movement of its Î±2
helix and Î²3 strand closer to the Î²GC flap and places
Met537 closer to hydrogen-bonding residues Î±GC Lys524 and Thr527
located on the Î²3 strand (Figures <xref rid="fig4" ref-type="fig">4</xref>B,D).
Thus, the Met537Asn mutation would enhance interactions between the
Î²GC flap and Î±GC by providing extra hydrogen bond contacts
between the two subunits. This hypothesis is strongly supported by
mutagenesis studies showing that two mutations abolishing hydrogen
bonds between Î±GC and the Î²GC flap (Î±GC Lys524Ala
and Î±GC Asp514Ala) in full-length sGC impair dimerization and
activity.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Similar mutations introduced
into adenylate cyclase yielded similar phenotypes. The C2a Lys1014Asn
mutation (analogous to the Î²GC Met537Asn mutation) increased
activity and affinity between the two subunits in the absence of forskolin
or Gs<sub>Î±</sub>.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> In addition,
the C1a Asp424Ala mutation (analogous to the Î±GC Asp514Ala mutation)
severely impaired activity and activation.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> (b) Other residues modulating sGC activity are located in the core
of the heterodimer at the interface between both subunits. The Î±GC
residues Glu526 and Cys595 are located in interfacial regions that
would undergo major conformational changes in the active form (Figure <xref rid="fig4" ref-type="fig">4</xref>B). On the basis of the structure of active AC,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> we hypothesize that Î±GC Glu526, Î±GC
Cys595, and Î²GC Thr474 form an interfacial hydrogen bond network
(equivalent to the C1a Lys436âC1a Asp505âC2a Thr939
adenylate cyclase triad), as these residues are also in the proximity
of each other in the modeled catalytic domain active structure (within
3.5 Ã of each other). This is strongly supported by studies showing
that mutations that abrogate the ability to form hydrogen bonds at
this interface severely impair sGC activity (Î±GC Cys595Tyr,
Î±GC Cys595Asp, Î±GC Glu526Ala, and Î±GC Cys595Asp/Glu526Lys)<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup> and adenylate cyclase activity (C1a Lys436Ala and C1a Asp505Ala).<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup> In contrast, the Î±GC Cys595Ser mutation dramatically increases
sGC basal activity.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> The Cys to Ser substitution
is often described as âsilentâ. However, the two amino
acids have distinct properties because of differences in size and
polarity between oxygen and sulfur. Thus, it is possible that the
Cys595Ser mutation would enhance the ability of this residue to form
hydrogen bonds.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> While we cannot rule
out the possibility that the Cys595Ser mutation may prevent Cys595
oxidation and subsequent enzyme inhibition, it is more likely that
Cys595 plays a key role in the communication between the two subunits.
Previous studies proposed that Cys595 may participate in binding of
the sGC stimulator YC-1 and modulate YC-1/NO activation.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> However, several groups have unambiguously ruled
out the possibility of binding of YC-1 to the catalytic domains.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref42">42</xref>â<xref ref-type="bibr" rid="ref49">49</xref></sup> Instead, we propose that both the interfacial flap and the hydrogen
bond network enhance interactions between the two catalytic subunits
and guide an optimal conformation of the active center necessary for
activity.</p>
        <fig id="fig4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Interfacial mutations in adenylate cyclase and sGC that modulate
enzyme activity underscore the key role of the heterodimeric interface
for catalysis. We mapped AC and sGC mutations on the structures of
the inactive Î±Î²GC heterodimer (A and B; PDB entry 4NI2) and the modeled
active structure of Î±Î²GC (C and D). The model for the
active conformation was generated with SWISSMODEL<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> by using active adenylate cyclase (PDB entry 1CJU) as a template.
Residues that affect sGC or AC activity map to two regions of the
Î±Î²GC heterodimer: (i) the interfacial hydrogen bond network
among sGC residues Î±GC Cys595, Î±GC Glu526, and Î²GC
Thr 474 (indicated by dashed green lines) and (ii) the sGC flap region
(Î²GC Met537) or the region interacting with the flap in the
partner subunit (Î±GC Asp514). Panels B and D are close-up views
of panels A and C, respectively.</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0005" id="gr4" position="float"/>
        </fig>
      </sec>
      <sec id="sec3.5">
        <title>Copurified Î±Î²GC Catalytic Domains Assemble as a
Mixture of Monomers, Homodimers, and Heterodimers</title>
        <p>To confirm
our structural prediction that the homodimeric Î²<sub>1</sub>Î²<sub>2</sub>GC interface is stronger than the heterodimeric
Î±Î²GC interface and the Î±Î±GC interface, we
used size-exclusion chromatography coupled to multiangle light scattering
(SEC-MALS) and nano-ESI/MS (Figure S1 of the <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>). Both the SEC (Figure S2A of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and SEC-MALS profiles (Figure S2C
of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) showed subtle
deviations from perfectly symmetric peaks at higher elution volumes,
suggesting slight heterogeneity in the sample composition. The molecular
weight determined by SEC-MALS ranged from 96 to 106% of the theoretical
molecular weight for the Î±Î²GC heterodimer. The subtle
tail of the elution peak at high elution volumes contained more Î±GC
than Î²GC as determined by sodium dodecyl sulfateâpolyacrylamide
gel electrophoresis (SDSâPAGE). This suggested that the Î±Î²GC
sample is a mixture of different oligomeric species in solution. However,
we were unable to distinguish the different species in solution by
SEC, MALS, or even mass spectrometry. Our result is not surprising
given our overwhelming success in crystallizing Î²Î²GC homodimers
over Î±Î²GC heterodimers and has important implications
when working with truncated sGC domains (see below).</p>
      </sec>
      <sec id="sec3.6">
        <title>Design of the
Shorter Î±GC661Î²GC Protein Allows Precise
Quantification of Heterodimers in Solution</title>
        <p>We showed above
that the copurified Î±Î²GC protein is heterogeneous both
in the length of the Î±GC subunit and in oligomer composition
and that we were unable to quantify the different species in solution.
This result is problematic for two reasons. First, structural mechanistic
studies of the Î±Î²GC catalytic domains in the presence
of metals, GTP, or GTP analogues require a reproducible homogeneous
heterodimeric sample, and second, specific activity calculations require
precise quantification of the Î±Î²GC heterodimers in solution,
as only heterodimers are catalytically active.</p>
        <p>Mass spectrometry
and crystal packing analysis suggested that we had crystallized the
heterodimeric Î±Î²GC catalytic domains with a truncated
Î±GC(466â662) subunit (<xref rid="notes-2" ref-type="notes">Supporting
Information</xref>). To increase the likelihood of obtaining high-quality
crystals of heterodimeric Î±Î²GC, we designed a shorter
Î±GC construct. The XtalPred and DISOPRED2 web servers<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> predicted the region of residues 662â690
of Î±GC to be disordered. Therefore, we designed the shorter
Î±GC661 construct that encompasses residues 466â661 after
TEV cleavage of the N-terminal tag. The size-exclusion profile of
copurified Î±GC661Î²GC showed two overlapping peaks (Figure
S2B of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) identified
as homodimers and heterodimers by SDSâPAGE.</p>
        <p>The calculated
molecular masses for Î±GC661 and Î²GC
differ by â¼3 kDa (Table <xref rid="tbl2" ref-type="other">2</xref>), allowing
us to discriminate all species present in the Î±GC661Î²GC
sample using mass spectrometry. First, we performed nano-ESI/MS for
each subunit purified independently. Like that of Î±GC (Figure
S1A of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>), the
spectrum for Î±GC661 showed that the protein was predominantly
monomeric (mass of 21642.9 Â± 18.3 Da) with a small amount of
homodimers (mass of 43403.1 Â± 5.5 Da) in a ratio of 79:21, as
determined by AUC analysis (Figure <xref rid="fig5" ref-type="fig">5</xref>A). As
seen previously, the spectrum for Î²GC and AUC analysis showed
that the monomer:dimer:tetramer ratio was 8:75:17 (Figure <xref rid="fig5" ref-type="fig">5</xref>B). These results confirmed our prediction based
on the crystal structure and modeling, and our size-exclusion experiments,
and showed that the <italic>K</italic><sub>D</sub> for homodimerization
of Î±GC661 was higher than that of Î²GC.</p>
        <fig id="fig5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Nano-ESI/MS and nano-ESI/MS/MS
(SID) reveal different oligomeric
species present in Î±GC661, Î²GC, and Î±GC661Î²GC
samples. (AâC) Nano-ESI/MS spectra were obtained by spraying
a 10 Î¼M protein sample in 0.1 M NH<sub>4</sub>OAc (pH 7.4).
(A) Î±GC661 exists mostly as a monomer. (B) Î²GC exists
predominantly as a dimer, with a small proportion of monomers and
tetramers also present. (C) Î±GC661Î²GC is present in approximately
equal amounts of monomer and dimer. The inset represents the spectrum
for Î±GC661Î²GC (10 Î¼M) in 80 mM NH<sub>4</sub>OAc
and 20 mM TEAA (pH 7.4). The major species present was the Î±GC661Î²GC
heterodimer. Î±GC661 and Î²GC monomers and Î±Î±GC661
and Î²Î²GC homodimers were also present. (DâF) Samples
(10 Î¼M) in 80 mM NH<sub>4</sub>OAc and 20 mM TEAA were sprayed,
and the +11 precursor ion was chosen for MS/MS analysis at an SID
voltage of 100 V. (D) Î±GC661 and (E) Î²GC dimers dissociate
to give Î±GC661 and Î²GC monomers, respectively. (F) Dissociation
of Î±GC661Î²GC results in an equal population of Î±GC661
and Î²GC monomers.</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0006" id="gr5" position="float"/>
        </fig>
        <p>Second, we performed nano-ESI/MS for copurified Î±GC661Î²GC
(Figure <xref rid="fig5" ref-type="fig">5</xref>C). The complex spectrum showed a
mixture of Î±GC661 monomers, Î²GC monomers, and Î±GC661Î²GC
heterodimers, with an experimental mass for the heterodimer of 46449.5
Â± 20.2 Da, which is close to the calculated value. After the
addition of TEAA to reduce the overall charge of the complex and better
separate the different charged species (Figure <xref rid="fig5" ref-type="fig">5</xref>C, inset), the spectrum showed a mixture of Î±GC661 monomers,
Î²GC monomers, Î±Î±GC661 homodimers, Î²Î²GC
homodimers, and Î±GC661Î²GC heterodimers. We further used
SID to confirm the identity of the different peaks (Figure <xref rid="fig5" ref-type="fig">5</xref>DâF). These results unambiguously confirmed
that the copurified Î±GC661Î²GC protein is a complex mixture
of different oligomeric species.</p>
        <p>To estimate the relative abundance
of each species, we measured
nano-ESI/MS spectra for Î±GC661, Î²GC, and Î±GC661Î²GC
proteins at various protein concentrations. For Î±GC661, we observed
only monomers and dimers. Thus, the <italic>K</italic><sub>D</sub> for Î±GC661 homodimerization was defined as the concentration
at which the concentrations of the Î±Î±GC661 dimer and the
Î±GC661 monomer are equal and was determined to be 30 Î¼M
(Figure S3A of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). For Î²GC, we observed several species in solution, including
monomers, dimers, and tetramers, complicating the determination of <italic>K</italic><sub>D</sub>. Furthermore, the ionization efficiency of
the Î²GC protein was significantly reduced at low concentrations.
As a result, we can only estimate that the <italic>K</italic><sub>D</sub> for the Î²Î²GC dimer is &lt;2 Î¼M (Figure
S3B of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). We
repeated this analysis for various concentrations of Î±GC661Î²GC
(Figure <xref rid="fig6" ref-type="fig">6</xref>). First, we noted that at high concentrations,
the relative abundance of all Î±GC species is almost equal to
that of all Î²GC species. However, at low concentrations, the
fraction of Î±GC is much higher than that of Î²GC. This
may be due to the decreased ionization efficiency of Î²GC at
low concentrations, as mentioned above. Therefore, we postulated that
the <italic>K</italic><sub>D</sub> for the Î±GC661Î²GC heterodimer
can be determined from the point at which the relative abundances
of Î±GC and Î±GC661Î²GC are equal, which corresponds
to a <italic>K</italic><sub>D</sub> of â¼6.9 Î¼M. Finally,
mass spectrometry analysis showed that mixing independently purified
Î±GC661 and Î²GC subunits yielded less Î±GC661Î²GC
heterodimer than purifying them together (data not shown).</p>
        <fig id="fig6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Determination
of <italic>K</italic><sub>D</sub> for Î±GC661Î²GC
heterodimers by nano-ESI/MS. Spectra for Î±GC661Î²GC were
obtained by spraying the protein sample in 80 mM NH<sub>4</sub>OAc
and 20 mM TEAA (pH 7.4). The concentration of Î±GC661Î²GC
was varied by performing serial dilutions from an initial 50 Î¼M
stock solution over a range of 0.6â20 Î¼M. The main panel
shows the changes in the relative abundance of Î±GC661Î²GC,
total Î±GC661, and total Î²GC as a function of protein concentration.
The insets show the relative abundance of the minor species in the
Î±GC661Î²GC sample as the concentration changes. For all
experiments, the abundance of a particular species was determined
by extracting its intensity from the ion mobility mobilogram that
is produced with the mass spectrum, and the area under the curve (AUC)
was determined using Origin.</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0007" id="gr6" position="float"/>
        </fig>
        <p>Overall, the use of the truncated Î±GC661 construct
allowed
us to determine the <italic>K</italic><sub>D</sub> for the Î±GC661Î²GC
heterodimer and quantify the amount of heterodimers present in solution
at any given concentration to calculate the true specific activity
normalized per mole of heterodimer. We firmly established that the
monomerâdimer dissociation constants for the catalytic domains
increase as follows: Î²Î²GC &lt; Î±Î²GC âª
Î±Î±GC. This is in contrast to earlier studies suggesting
that the <italic>K</italic><sub>D</sub> of Î²Î²GC or Î±Î±GC
homodimers was much higher than the <italic>K</italic><sub>D</sub> of the Î±Î²GC heterodimer.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> These conflicting results may be due to distinct techniques used
to characterize oligomeric assemblies. As opposed to low-resolution
size-exclusion chromatography used previously,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> we used native mass spectrometry coupled to SID, which
affords high accuracy in the stoichiometry of noncovalent complexes
while preserving a nativelike quaternary structure.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> Importantly, our results support and extend a recent study
showing that homodimers and heterodimers of the catalytic domains
are both present in solution.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></p>
        <p>Our
results have important implications for activity assay measurements
with truncated sGC constructs commonly used by various laboratories.
(i) A protein concentration well above the <italic>K</italic><sub>D</sub> should be chosen to ensure adequate heterodimer formation
in the reaction mixture, and (ii) the true specific activity should
be calculated on the basis of the heterodimer concentration only,
as monomers and homodimers display no activity but contribute to the
total protein concentration. While these requirements may not apply
to wild-type full-length sGC, which mostly forms heterodimers <italic>in vitro</italic>, these results are critical for accurate activity
assay measurements with mutant full-length sGC that show impaired
dimerization.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref52">52</xref>â<xref ref-type="bibr" rid="ref54">54</xref></sup></p>
        <p>Finally, our mass spectrometry approach to
determine dimerization
dissociation constants can be applied to truncated sGC constructs,
encompassing various domains to precisely determine the contribution
of each domain to heterodimerization of full-length sGC. Dimerization
determinants were shown to be predominantly contained in the HNOXA
and coiled-coil (CC) domains,<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref53">53</xref>â<xref ref-type="bibr" rid="ref56">56</xref></sup> with some contribution from the catalytic domains.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> However, X-ray structures of homodimers were determined for HNOXA
and CC domains,<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> suggesting that, under these
conditions, both domains can also homodimerize with <italic>K</italic><sub>D</sub> values that were estimated to be in the micromolar range.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> While a major role for the CC domain was proposed,<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> the precise determinants favoring sGC heterodimerization
remain ambiguous and warrant further studies.</p>
      </sec>
      <sec id="sec3.7">
        <title>Isolated Catalytic Domains
Display Low Activity Despite Forming
Heterodimers</title>
        <p>Because we crystallized the apo Î±Î²GC
heterodimer, we wanted to confirm that the isolated catalytic domains
were nonetheless active. Others have shown that the regulatory N-terminal
Î²HNOXâHNOXA domains inhibit the activity of the catalytic
domains.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Thus, in the absence of the regulatory domains,
the isolated Î±Î²GC domains should be as active as activated
full-length sGC. We measured cGMP formation with our purified Î±Î²GC
and Î±GC661Î²GC proteins, and human full-length sGC that
was overexpressed in baculovirus (kind gift from E. Martin, The University
of Texas Health Science Center at Houston, Houston, TX). We used Î±GC
protein purified independently as a negative control.</p>
        <p>The results
presented above show that the copurified Î±Î²GC protein
is a heterogeneous mixture of monomers, homodimers, and heterodimers.
Because heterodimeric Î±Î²GC is the only catalytically active
species, the true specific activity should be calculated by normalizing
to the heterodimer concentration. This has proven to be difficult
with wild-type Î±Î²GC protein (see above). The design of
the truncated Î±GC661Î²GC construct has allowed us to calculate
the ratio of heterodimers at different total protein concentrations.
First, we showed that Î±GC661Î²GC [1.2 + 0.4 or â
0.3 fmol of cGMP min<sup>â1</sup> (pmol of enzyme)<sup>â1</sup>] and untruncated Î±Î²GC catalytic domains [1.8 + 0.7 or
â 0.5 fmol of cGMP min<sup>â1</sup> (pmol of enzyme)<sup>â1</sup>] display comparable activity. Thus, the remainder
of the analysis is based on Î±GC661Î²GC for which we can
calculate the true specific activity by normalizing to heterodimer
concentration based on mass spectrometry data. For full-length sGC,
mass spectrometry analysis showed that the protein is 100% heterodimeric
at the concentration used for the cGMP reaction (data not shown).
Importantly, copurified Î±GC661Î²GC displayed only a fraction
(0.01%) of the specific activity of basal full-length sGC in the presence
of Mg<sup>2+</sup> (Table <xref rid="tbl3" ref-type="other">3</xref>). In the presence
of Mn<sup>2+</sup>, the activities of Î±GC661Î²GC and full-length
sGC increased (779- and 2-fold, respectively), but Î±GC661Î²GC
still displayed &lt;6% of the activity of full-length sGC. These results
suggest that the isolated catalytic domains are not catalytically
competent compared to basal full-length sGC, despite their ability
to heterodimerize. Our structural studies of Î±Î²GC catalytic
domains corroborate this result, as we crystallized the heterodimer
in an inactive conformation. In the related adenylate cyclase, binding
of Gs<sub>Î±</sub>, forskolin, and ATP induces conformational
changes leading to a closed and active catalytic center.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> A similar mechanism is likely for sGC, whereby
the catalytic center alternates between inactive and active conformations
via structural rearrangements.</p>
        <table-wrap id="tbl3" position="float">
          <label>Table 3</label>
          <caption>
            <title>Guanylate Cyclase
Activity<xref rid="t3fn1" ref-type="table-fn">a</xref></title>
          </caption>
          <table frame="hsides" rules="groups" border="0">
            <colgroup>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
            </colgroup>
            <thead>
              <tr>
                <th style="border:none;" align="center">Â </th>
                <th colspan="2" align="center">Î±GC661Î²GC<hr/></th>
                <th colspan="2" align="center">basal
full-length sGC<hr/></th>
                <th style="border:none;" align="center">Î±GC</th>
              </tr>
              <tr>
                <th style="border:none;" align="center">Â </th>
                <th style="border:none;" align="center">Mg<sup>2+</sup></th>
                <th style="border:none;" align="center">Mn<sup>2+</sup></th>
                <th style="border:none;" align="center">Mg<sup>2+</sup></th>
                <th style="border:none;" align="center">Mn<sup>2+</sup></th>
                <th style="border:none;" align="center">Mg<sup>2+</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td style="border:none;" align="left">specific activity
[fmol of cGMP min<sup>â1</sup> (pmol
of enzyme)<sup>â1</sup>]</td>
                <td style="border:none;" align="left">1.2</td>
                <td style="border:none;" align="left">899.9</td>
                <td style="border:none;" align="left">10075.5</td>
                <td style="border:none;" align="left">20578.5</td>
                <td style="border:none;" align="left">0.5</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">upper bound error<xref rid="t3fn2" ref-type="table-fn">b</xref></td>
                <td style="border:none;" align="left">0.4</td>
                <td style="border:none;" align="left">259.8</td>
                <td style="border:none;" align="left">3163.7</td>
                <td style="border:none;" align="left">5819.0</td>
                <td style="border:none;" align="left">0.3</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">lower bound error<xref rid="t3fn2" ref-type="table-fn">b</xref></td>
                <td style="border:none;" align="left">0.3</td>
                <td style="border:none;" align="left">200.7</td>
                <td style="border:none;" align="left">2300.2</td>
                <td style="border:none;" align="left">4433.3</td>
                <td style="border:none;" align="left">0.2</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">relative
abundance of the heterodimer (%)<xref rid="t3fn3" ref-type="table-fn">c</xref></td>
                <td style="border:none;" align="left">82.5</td>
                <td style="border:none;" align="left">82.5</td>
                <td style="border:none;" align="left">100</td>
                <td style="border:none;" align="left">100</td>
                <td style="border:none;" align="left">NA<xref rid="t3fn5" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">adjusted
specific activity [fmol of cGMP min<sup>â1</sup> (pmol of heterodimer)<sup>â1</sup>]</td>
                <td style="border:none;" align="left">1.4</td>
                <td style="border:none;" align="left">1090.8</td>
                <td style="border:none;" align="left">10075.5</td>
                <td style="border:none;" align="left">20578.5</td>
                <td style="border:none;" align="left">NA<xref rid="t3fn5" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">upper bound error<xref rid="t3fn2" ref-type="table-fn">b</xref></td>
                <td style="border:none;" align="left">0.5</td>
                <td style="border:none;" align="left">314.9</td>
                <td style="border:none;" align="left">3163.7</td>
                <td style="border:none;" align="left">5819.0</td>
                <td style="border:none;" align="left">NA<xref rid="t3fn5" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">lower bound error<xref rid="t3fn2" ref-type="table-fn">b</xref></td>
                <td style="border:none;" align="left">0.4</td>
                <td style="border:none;" align="left">243.2</td>
                <td style="border:none;" align="left">2300.2</td>
                <td style="border:none;" align="left">4433.3</td>
                <td style="border:none;" align="left">NA<xref rid="t3fn5" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left">activity
normalized to full-length sGC (%)</td>
                <td style="border:none;" align="left">0.01</td>
                <td style="border:none;" align="left">5.3</td>
                <td style="border:none;" align="left">100</td>
                <td style="border:none;" align="left">100</td>
                <td style="border:none;" align="left">NA<xref rid="t3fn5" ref-type="table-fn">d</xref></td>
              </tr>
              <tr>
                <td style="border:none;" align="left"><italic>x</italic>-fold
increase in specific activity with
Mn<sup>2+</sup></td>
                <td style="border:none;" align="left">1</td>
                <td style="border:none;" align="left">779</td>
                <td style="border:none;" align="left">1</td>
                <td style="border:none;" align="left">2</td>
                <td style="border:none;" align="left">NA<xref rid="t3fn5" ref-type="table-fn">d</xref></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="t3fn1">
              <label>a</label>
              <p>The reaction was performed as described
in <xref rid="sec2" ref-type="other">Experimental Procedures</xref>.</p>
            </fn>
            <fn id="t3fn2">
              <label>b</label>
              <p>Error boundaries describe the 95%
confidence interval.</p>
            </fn>
            <fn id="t3fn3">
              <label>c</label>
              <p>Determined
by mass spectrometry.</p>
            </fn>
            <fn id="t3fn5">
              <label>d</label>
              <p>Not
applicable.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>We propose that
other sGC domains (including the coiled coil) will
guide conformational changes leading to an optimal alignment of the
active site residues. This model is supported by recent data showing
that an Î±Î²HNOXA-CC-GC construct displays activity comparable
to that of full-length sGC,<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> and by our
results showing that substitution of Mg<sup>2+</sup> with Mn<sup>2+</sup> increases the basal activity of full-length sGC and Î±GC661Î²GC
(Table <xref rid="tbl3" ref-type="other">3</xref>). We propose that Mn<sup>2+</sup> ions
allow catalysis in both proteins without the need for the catalytic
domains to undergo the transition to an optimal conformation. While
Mg<sup>2+</sup> requires a very specific coordination geometry,<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> Mn<sup>2+</sup> has been shown to be less stringent.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> In DNA polymerases, Mn<sup>2+</sup> easily replaces
Mg<sup>2+</sup> but it also allows reactions to occur with mutated
catalytic residues and decreased substrate specificity because of
its higher tolerance for suboptimal metal coordination.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> Similarly, for full-length sGC and isolated
Î±Î²GC catalytic domains, Mn<sup>2+</sup> may favor a suboptimal
conformation of the catalytic domains. This hypothesis is supported
by studies showing that NO and/or YC-1 fails to fully activate sGC
in the presence of Mn<sup>2+</sup>,<sup><xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref55">55</xref>,<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref></sup> suggesting that the
enzyme is locked in an intermediate catalytic state. In conclusion,
our activity measurements strongly support a role for other sGC domains
in promoting a competent conformation of the active center.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4">
      <title>Discussion</title>
      <p>The combined structural, biophysical, and mass spectrometry analyses
presented here clarify widely accepted ideas regarding heterodimerization
and activity of the isolated catalytic subunits of sGC and further
provide the basis for understanding the regulation of sGC catalytic
activity. We propose a novel role for interfacial structural elements
in modulating the conformation of the active site for optimal activity.
Finally, our results allow us to propose a comprehensive regulatory
model in which distinct domainâdomain interactions in sGC prevent
or guide an optimal conformation of the sGC catalytic center associated
with high activity.</p>
      <sec id="sec4.1">
        <title>Overall Structure of Î±Î²GC Catalytic
Domains and
Comparison with the Mutant Structure</title>
        <p>To determine whether
conformational changes are required for catalytic activity, we determined
the X-ray structure of the Î±Î²GC catalytic domains from
human sGC. We successfully obtained crystals of the wild-type catalytic
domains, without the need for an engineered disulfide.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> In our case, cleavage of the 28 C-terminal amino
acids of Î±GC yielded a small amount of truncated Î±GC662Î²GC
catalytic domains that formed favorable crystal contacts, unlike the
untruncated catalytic domains. The structural comparison of the mutant
and wild-type Î±Î²GC catalytic domains reveals that the
two structures are very similar but exhibit subtle differences at
the dimer interface. Both our structure and that of the mutant Î±Î²GC
catalytic domains were obtained in the absence of metal and nucleotide
and show inactive conformations of the active center. This is evidenced
by the extended loop conformation of the substrate binding regions
at the core of the dimer interface, and the drastically different
orientation of the Î±GC subunit relative to the Î²GC subunit,
compared to the structure of active adenylate cyclase catalytic domains.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Potent sGC inhibitors have recently been described.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> These nucleotide analogues show <italic>K</italic><sub>i</sub> values in the low nanomolar range and were predicted
by docking to bind to an active conformation of the catalytic domains.
We are currently exploring the use of these molecules to favor the
crystallization of the active heterodimeric catalytic domains of sGC.</p>
      </sec>
      <sec id="sec4.2">
        <title>Residues at the Heterodimeric Interface Guide an Optimal Conformation
of the Active Center</title>
        <p>Our structure allowed us to propose
a key role for structural elements of the catalytic domains in guiding
an optimal conformation of the active center for activity. Our mass
spectrometry studies, yielding a relatively weak heterodimerization
affinity, and our structural comparisons strongly suggest that the
dimer interface is flexible for achieving structural transitions from
an inactive open form to an activated closed form, which has been
observed for adenylate cyclase.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> On the
basis of our structural studies and mutagenesis data,<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup> we propose that both the interfacial
flap and the hydrogen bond network enhance interactions between the
two catalytic subunits and guide an optimal conformation of the active
center necessary for activity. Studies are now underway to determine
whether these activating mutations can facilitate structural studies
of the sGC catalytic domains in the active state.</p>
      </sec>
      <sec id="sec4.3">
        <title>The Cyclase
Domains Require Other sGC Domains for Optimal Activity</title>
        <p>Our
activity assay results demonstrate that even in the absence
of the regulatory domains, additional sGC domain interactions are
required to guide the appropriate conformation of the catalytic subunits
associated with high activity. We propose that sGC activity is modulated
by domainâdomain interactions that allow the catalytic domains
to undergo the transition from an inactive to an active conformation
according to the following model: in the basal state, catalytic domains
are constrained in a suboptimal conformation via inhibitory interactions
with sGC domains, including the N-terminal Î²HNOX (and HNOXA)
domain,<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> which is itself maintained in an inhibited
conformation by the Î±HNOX and Î±HNOXA domains.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Binding of NO and/or activators releases these
inhibitory interactions and induces conformational changes transmitted
to the catalytic domains via the coiled-coil domain<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> to yield the activated state (Figure <xref rid="fig7" ref-type="fig">7</xref>). How the conformational transitions of these domains are orchestrated
in sGC is still unknown. However, recent electron microscopy and hydrogenâdeuterium
exchange mass spectrometry suggest that full-length sGC presents multiple
conformations with several interdomain pivot points allowing conformational
changes to be transmitted from the regulatory domains to the catalytic
domains.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref65">65</xref></sup> The observed âclosingâ of
the catalytic interface upon NO binding<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> corroborates our proposal that other sGC domains, including the
coiled coil, will guide conformational changes in the catalytic domains,
leading to an optimal alignment of the active site residues for full
sGC activity.</p>
        <fig id="fig7" position="float">
          <label>Figure 7</label>
          <caption>
            <p>Model for domainâdomain interactions that influence
the
conformation of the heterodimeric GC interface to modulate the activity
of sGC. In state 1 (âbasalâ), competing domainâdomain
interactions yield sGC with low activity. While some sGC domains (including
the coiled coil) promote conformational changes of the catalytic subunits,
the regulatory Î²HNOX domain (and possibly the HNOXA domain)
inhibits activity via direct binding to Î±GC. Mutations in the
Î±GC subunit (Cys595Asp and Cys595Tyr) also prevent conformational
changes in the active site. In state 2 (âactivatedâ),
binding of NO to Î²HNOX removes the inhibition and allows further
conformational changes of the catalytic domains to yield fully active
sGC. Mutations in catalytic subunits (Î²GC Met537Asn and Î±GC
Cys595Ser) also yield an âactivatedâ phenotype. In state
3 (âintermediateâ), Mn<sup>2+</sup> allows catalysis
with a nonoptimal conformation of the catalytic domains. However,
the enzyme is now locked in an intermediate state and cannot be further
activated by NO and/or activators. The catalytic domains (represented
as a blue and orange yin-yang) are in an inactive conformation (poor
alignment) in states 1 and 3, and an active conformation in state
2 (perfect alignment of yin and yang).</p>
          </caption>
          <graphic xlink:href="bi-2014-00129k_0008" id="gr7" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="sec5">
      <title>Conclusions</title>
      <p>Our results allow us to propose that novel
structural elements,
the interfacial Î²-flap and hydrogen bond network, play a key
role in sGC catalytic activity by enhancing interactions between the
two catalytic subunits and guiding the active center to an optimal
conformation.</p>
      <p>This is the first study demonstrating that the
catalytic Î±Î²GC
domains require additional sGC domains for activity, despite their
ability to heterodimerize. Overall, collective results provide evidence
that other sGC domains modulate the relative orientation of the catalytic
subunits and control the proper orientation of key residues in the
catalytic domain for full enzyme activity. The fine balance between
inhibitory and activating domainâdomain interactions is modulated
by NO and/or activators. As such, small molecules that influence the
orientation of the catalytic subunits have a strong potential to shift
this equilibrium. This work provides the basis for a novel model for
sGC activation and opens additional drug discovery routes for targeting
the NOâcGMP pathway.</p>
    </sec>
  </body>
  <back>
    <notes id="notes-2" notes-type="si">
      <title>Supporting Information Available</title>
      <p>Movie
showing the superimposition
of the wild-type and mutant (PDB entry 3UVJ) heterodimeric structures of the sGC
catalytic domains (Movie S1), additional results, Table S1, sequence
alignment, and Figures S1âS3. This material is available free
of charge via the Internet at <uri xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p>
    </notes>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="sifile1">
        <media xlink:href="bi500129k_si_001.pdf">
          <caption>
            <p>bi500129k_si_001.pdf</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="si55">
        <media xlink:href="bi500129k_si_003.mov">
          <caption>
            <p>bi500129k_si_003.mov</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <notes id="NOTES-d2767e1837-autogenerated" notes-type="conflict-of-interest">
      <p>The authors
declare no
competing financial interest.</p>
    </notes>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank
Susan E. Tsutakawa, Robert P. Rambo, Scott Classen,
Thomas Miller, and James Fishbein for critical reading of the manuscript,
technical support, and insightful discussions. Part of this work was
conducted at the Advanced Light Source (ALS), a national user facility
operated by Lawrence Berkeley National Laboratory on behalf of the
Department of Energy (DOE), Office of Basic Energy Sciences, through
the Integrated Diffraction Analysis Technologies (IDAT) program, supported
by the DOE Office of Biological and Environmental Research. Additional
support comes from the National Institute of Health project MINOS
(R01GM105404).</p>
    </ack>
    <glossary id="dl1">
      <def-list>
        <title>Abbreviations</title>
        <def-item>
          <term>sGC</term>
          <def>
            <p>full-length soluble guanylyl cyclase
or soluble guanylate cyclase</p>
          </def>
        </def-item>
        <def-item>
          <term>CC</term>
          <def>
            <p>coiled coil</p>
          </def>
        </def-item>
        <def-item>
          <term>H-NOX or HNOX</term>
          <def>
            <p>heme-nitric oxide oxygen binding</p>
          </def>
        </def-item>
        <def-item>
          <term>HNOXA</term>
          <def>
            <p>HNOX-associated</p>
          </def>
        </def-item>
        <def-item>
          <term>GC</term>
          <def>
            <p>guanylate cyclase catalytic domain</p>
          </def>
        </def-item>
        <def-item>
          <term>SEC-MALS</term>
          <def>
            <p>size-exclusion chromatography
coupled to multiangle light scattering</p>
          </def>
        </def-item>
        <def-item>
          <term>SID</term>
          <def>
            <p>surface-induced dissociation</p>
          </def>
        </def-item>
        <def-item>
          <term>Î±Î²GC</term>
          <def>
            <p>construct
containing only the Î± and Î² catalytic domains of sGC</p>
          </def>
        </def-item>
        <def-item>
          <term>rmsd</term>
          <def>
            <p>root-mean-square
deviation.</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <mixed-citation publication-type="journal" id="cit1"><name><surname>Voetsch</surname><given-names>B.</given-names></name>; <name><surname>Jin</surname><given-names>R. C.</given-names></name>; <name><surname>Loscalzo</surname><given-names>J.</given-names></name> (<year>2004</year>) <article-title>Nitric oxide
insufficiency and atherothrombosis</article-title>. <source>Histochem.
Cell Biol.</source>
<volume>122</volume>, <fpage>353</fpage>â<lpage>367</lpage>.<pub-id pub-id-type="pmid">15338226</pub-id></mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation publication-type="journal" id="cit2"><name><surname>Ghofrani</surname><given-names>H.-A.</given-names></name>; <name><surname>GaliÃ¨</surname><given-names>N.</given-names></name>; <name><surname>Grimminger</surname><given-names>F.</given-names></name>; <name><surname>GrÃ¼nig</surname><given-names>E.</given-names></name>; <name><surname>Humbert</surname><given-names>M.</given-names></name>; <name><surname>Jing</surname><given-names>Z.-C.</given-names></name>; <name><surname>Keogh</surname><given-names>A. M.</given-names></name>; <name><surname>Langleben</surname><given-names>D.</given-names></name>; <name><surname>Kilama</surname><given-names>M. O.</given-names></name>; <name><surname>Fritsch</surname><given-names>A.</given-names></name>; <name><surname>Neuser</surname><given-names>D.</given-names></name>; <name><surname>Rubin</surname><given-names>L. J.</given-names></name> (<year>2013</year>) <article-title>Riociguat
for the Treatment of Pulmonary Arterial Hypertension</article-title>. <source>N. Engl. J. Med.</source>
<volume>369</volume>, <fpage>330</fpage>â<lpage>340</lpage>.<pub-id pub-id-type="pmid">23883378</pub-id></mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation publication-type="journal" id="cit3"><name><surname>Follmann</surname><given-names>M.</given-names></name>; <name><surname>Griebenow</surname><given-names>N.</given-names></name>; <name><surname>Hahn</surname><given-names>M. G.</given-names></name>; <name><surname>Hartung</surname><given-names>I.</given-names></name>; <name><surname>Mais</surname><given-names>F.-J.</given-names></name>; <name><surname>Mittendorf</surname><given-names>J.</given-names></name>; <name><surname>SchÃ¤fer</surname><given-names>M.</given-names></name>; <name><surname>Schirok</surname><given-names>H.</given-names></name>; <name><surname>Stasch</surname><given-names>J.-P.</given-names></name>; <name><surname>Stoll</surname><given-names>F.</given-names></name>; <name><surname>Straub</surname><given-names>A.</given-names></name> (<year>2013</year>) <article-title>The Chemistry and Biology of Soluble
Guanylate Cyclase Stimulators and Activators</article-title>. <source>Angew. Chem., Int. Ed.</source>
<volume>52</volume>, <fpage>9442</fpage>â<lpage>9462</lpage>.</mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation publication-type="journal" id="cit4"><name><surname>Conole</surname><given-names>D.</given-names></name>; <name><surname>Scott</surname><given-names>L.</given-names></name> (<year>2013</year>) <article-title>Riociguat: First global approval</article-title>. <source>Drugs</source>
<volume>73</volume>, <fpage>1967</fpage>â<lpage>1975</lpage>.<pub-id pub-id-type="pmid">24218053</pub-id></mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation publication-type="book" id="cit5"><person-group person-group-type="allauthors"><name><surname>Stasch</surname><given-names>J.-P.</given-names></name>, and <name><surname>Evgenov</surname><given-names>O. V.</given-names></name></person-group> (<year>2013</year>) <article-title>Soluble Guanylate Cyclase Stimulators
in Pulmonary Hypertension</article-title>. In <source>Pharmacotherapy
of Pulmonary Hypertension</source> (<person-group person-group-type="editor"><name><surname>Humbert</surname><given-names>M.</given-names></name>, <name><surname>Evgenov</surname><given-names>O. V.</given-names></name>, and <name><surname>Stasch</surname><given-names>J.-P.</given-names></name></person-group>, Eds.) pp <fpage>279</fpage>â<lpage>313</lpage>, <publisher-name>Springer</publisher-name>, <publisher-loc>Berlin</publisher-loc>.</mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation publication-type="journal" id="cit6"><name><surname>Moncada</surname><given-names>S.</given-names></name>; <name><surname>Higgs</surname><given-names>A.</given-names></name> (<year>1993</year>) <article-title>The <sc>l</sc>-Arginine-Nitric Oxide Pathway</article-title>. <source>N. Engl. J. Med.</source>
<volume>329</volume>, <fpage>2002</fpage>â<lpage>2012</lpage>.<pub-id pub-id-type="pmid">7504210</pub-id></mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation publication-type="journal" id="cit7"><name><surname>Naseem</surname><given-names>K.</given-names></name> (<year>2005</year>) <article-title>The role of
nitric oxide in cardiovascular diseases</article-title>. <source>Mol.
Aspects Med.</source>
<volume>26</volume>, <fpage>33</fpage>â<lpage>65</lpage>.<pub-id pub-id-type="pmid">15722114</pub-id></mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation publication-type="journal" id="cit8"><name><surname>Thomas</surname><given-names>D. D.</given-names></name>; <name><surname>Ridnour</surname><given-names>L. A.</given-names></name>; <name><surname>Isenberg</surname><given-names>J. S.</given-names></name>; <name><surname>Flores-Santana</surname><given-names>W.</given-names></name>; <name><surname>Switzer</surname><given-names>C. H.</given-names></name>; <name><surname>Donzelli</surname><given-names>S.</given-names></name>; <name><surname>Hussain</surname><given-names>P.</given-names></name>; <name><surname>Vecoli</surname><given-names>C.</given-names></name>; <name><surname>Paolocci</surname><given-names>N.</given-names></name>; <name><surname>Ambs</surname><given-names>S.</given-names></name>; <name><surname>Colton</surname><given-names>C. A.</given-names></name>; <name><surname>Harris</surname><given-names>C. C.</given-names></name>; <name><surname>Roberts</surname><given-names>D. D.</given-names></name>; <name><surname>Wink</surname><given-names>D. A.</given-names></name> (<year>2008</year>) <article-title>The chemical biology
of nitric oxide:
Implications in cellular signaling</article-title>. <source>Free Radical
Biol. Med.</source>
<volume>45</volume>, <fpage>18</fpage>â<lpage>31</lpage>.<pub-id pub-id-type="pmid">18439435</pub-id></mixed-citation>
      </ref>
      <ref id="ref9">
        <mixed-citation publication-type="journal" id="cit9"><name><surname>Isenberg</surname><given-names>J. S.</given-names></name>; <name><surname>Ridnour</surname><given-names>L. A.</given-names></name>; <name><surname>Perruccio</surname><given-names>E. M.</given-names></name>; <name><surname>Espey</surname><given-names>M. G.</given-names></name>; <name><surname>Wink</surname><given-names>D. A.</given-names></name>; <name><surname>Roberts</surname><given-names>D. D.</given-names></name> (<year>2005</year>) <article-title>Thrombospondin-1
inhibits endothelial cell responses
to nitric oxide in a cGMP-dependent manner</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>102</volume>, <fpage>13141</fpage>â<lpage>13146</lpage>.<pub-id pub-id-type="pmid">16150726</pub-id></mixed-citation>
      </ref>
      <ref id="ref10">
        <mixed-citation publication-type="journal" id="cit10"><name><surname>Miller</surname><given-names>T. W.</given-names></name>; <name><surname>Isenberg</surname><given-names>J. S.</given-names></name>; <name><surname>Roberts</surname><given-names>D. D.</given-names></name> (<year>2010</year>) <article-title>Thrombospondin-1 is an inhibitor
of pharmacological activation of soluble guanylate cyclase: TSP-1
inhibits sGC activators</article-title>. <source>Br. J. Pharmacol.</source>
<volume>159</volume>, <fpage>1542</fpage>â<lpage>1547</lpage>.<pub-id pub-id-type="pmid">20233213</pub-id></mixed-citation>
      </ref>
      <ref id="ref11">
        <mixed-citation publication-type="journal" id="cit11"><name><surname>Ramanathan</surname><given-names>S.</given-names></name>; <name><surname>Mazzalupo</surname><given-names>S.</given-names></name>; <name><surname>Boitano</surname><given-names>S.</given-names></name>; <name><surname>Montfort</surname><given-names>W. R.</given-names></name> (<year>2011</year>) <article-title>Thrombospondin-1
and Angiotensin II Inhibit Soluble Guanylyl Cyclase through an Increase
in Intracellular Calcium Concentration</article-title>. <source>Biochemistry</source>
<volume>50</volume>, <fpage>7787</fpage>â<lpage>7799</lpage>.<pub-id pub-id-type="pmid">21823650</pub-id></mixed-citation>
      </ref>
      <ref id="ref12">
        <mixed-citation publication-type="journal" id="cit12"><name><surname>Kamisaki</surname><given-names>Y.</given-names></name>; <name><surname>Saheki</surname><given-names>S.</given-names></name>; <name><surname>Nakane</surname><given-names>M.</given-names></name>; <name><surname>Palmieri</surname><given-names>J. A.</given-names></name>; <name><surname>Kuno</surname><given-names>T.</given-names></name>; <name><surname>Chang</surname><given-names>B. Y.</given-names></name>; <name><surname>Waldman</surname><given-names>S. A.</given-names></name>; <name><surname>Murad</surname><given-names>F.</given-names></name> (<year>1986</year>) <article-title>Soluble guanylate cyclase
from rat lung exists as a heterodimer</article-title>. <source>J. Biol.
Chem.</source>
<volume>261</volume>, <fpage>7236</fpage>â<lpage>7241</lpage>.<pub-id pub-id-type="pmid">2872214</pub-id></mixed-citation>
      </ref>
      <ref id="ref13">
        <mixed-citation publication-type="journal" id="cit13"><name><surname>Pellicena</surname><given-names>P.</given-names></name>; <name><surname>Karow</surname><given-names>D. S.</given-names></name>; <name><surname>Boon</surname><given-names>E. M.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name>; <name><surname>Kuriyan</surname><given-names>J.</given-names></name> (<year>2004</year>) <article-title>Crystal structure
of an oxygen-binding heme domain related to soluble guanylate cyclases</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>101</volume>, <fpage>12854</fpage>â<lpage>12859</lpage>.<pub-id pub-id-type="pmid">15326296</pub-id></mixed-citation>
      </ref>
      <ref id="ref14">
        <mixed-citation publication-type="journal" id="cit14"><name><surname>Nioche</surname><given-names>P.</given-names></name>; <name><surname>Berka</surname><given-names>V.</given-names></name>; <name><surname>Vipond</surname><given-names>J.</given-names></name>; <name><surname>Minton</surname><given-names>N.</given-names></name>; <name><surname>Tsai</surname><given-names>A. L.</given-names></name>; <name><surname>Raman</surname><given-names>C. S.</given-names></name> (<year>2004</year>) <article-title>Femtomolar sensitivity of a NO sensor from <italic>Clostridium botulinum</italic></article-title>. <source>Science</source>
<volume>306</volume>, <fpage>1550</fpage>â<lpage>1553</lpage>.<pub-id pub-id-type="pmid">15472039</pub-id></mixed-citation>
      </ref>
      <ref id="ref15">
        <mixed-citation publication-type="journal" id="cit15"><name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Sayed</surname><given-names>N.</given-names></name>; <name><surname>Beuve</surname><given-names>A.</given-names></name>; <name><surname>van den Akker</surname><given-names>F.</given-names></name> (<year>2007</year>) <article-title>NO and CO
differentially activate soluble guanylyl cyclase via a heme pivot-bend
mechanism</article-title>. <source>EMBO J.</source>
<volume>26</volume>, <fpage>578</fpage>â<lpage>588</lpage>.<pub-id pub-id-type="pmid">17215864</pub-id></mixed-citation>
      </ref>
      <ref id="ref16">
        <mixed-citation publication-type="journal" id="cit16"><name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Sayed</surname><given-names>N.</given-names></name>; <name><surname>Baskaran</surname><given-names>P.</given-names></name>; <name><surname>Beuve</surname><given-names>A.</given-names></name>; <name><surname>van den
Akker</surname><given-names>F.</given-names></name> (<year>2008</year>) <article-title>PAS-mediated dimerization of soluble guanylyl cyclase revealed by
signal transduction histidine kinase domain crystal structure</article-title>. <source>J. Biol. Chem.</source>
<volume>283</volume>, <fpage>1167</fpage>â<lpage>1178</lpage>.<pub-id pub-id-type="pmid">18006497</pub-id></mixed-citation>
      </ref>
      <ref id="ref17">
        <mixed-citation publication-type="journal" id="cit17"><name><surname>Purohit</surname><given-names>R.</given-names></name>; <name><surname>Weichsel</surname><given-names>A.</given-names></name>; <name><surname>Montfort</surname><given-names>W. R.</given-names></name> (<year>2013</year>) <article-title>Crystal structure of the Î±
subunit PAS domain from soluble guanylyl cyclase</article-title>. <source>Protein Sci.</source>
<volume>22</volume>, <fpage>1439</fpage>â<lpage>1444</lpage>.<pub-id pub-id-type="pmid">23934793</pub-id></mixed-citation>
      </ref>
      <ref id="ref18">
        <mixed-citation publication-type="journal" id="cit18"><name><surname>Rauch</surname><given-names>A.</given-names></name>; <name><surname>Leipelt</surname><given-names>M.</given-names></name>; <name><surname>Russwurm</surname><given-names>M.</given-names></name>; <name><surname>Steegborn</surname><given-names>C.</given-names></name> (<year>2008</year>) <article-title>Crystal structure
of the guanylyl cyclase Cya2</article-title>. <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
<volume>105</volume>, <fpage>15720</fpage>â<lpage>15725</lpage>.<pub-id pub-id-type="pmid">18840690</pub-id></mixed-citation>
      </ref>
      <ref id="ref19">
        <mixed-citation publication-type="journal" id="cit19"><name><surname>Winger</surname><given-names>J.
A.</given-names></name>; <name><surname>Derbyshire</surname><given-names>E. R.</given-names></name>; <name><surname>Lamers</surname><given-names>M. H.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name>; <name><surname>Kuriyan</surname><given-names>J.</given-names></name> (<year>2008</year>) <article-title>The crystal
structure of the catalytic domain of a eukaryotic guanylate cyclase</article-title>. <source>BMC Struct. Biol.</source>
<volume>8</volume>, <fpage>42</fpage>.<pub-id pub-id-type="pmid">18842118</pub-id></mixed-citation>
      </ref>
      <ref id="ref20">
        <mixed-citation publication-type="journal" id="cit20"><name><surname>Allerston</surname><given-names>C. K.</given-names></name>; <name><surname>von Delft</surname><given-names>F.</given-names></name>; <name><surname>Gileadi</surname><given-names>O.</given-names></name> (<year>2013</year>) <article-title>Crystal Structures of the Catalytic
Domain of Human Soluble Guanylate Cyclase</article-title>. <source>PLoS
One</source>
<volume>8</volume>, <fpage>e57644</fpage>.<pub-id pub-id-type="pmid">23505436</pub-id></mixed-citation>
      </ref>
      <ref id="ref21">
        <mixed-citation publication-type="journal" id="cit21"><name><surname>Campbell</surname><given-names>M. G.</given-names></name>; <name><surname>Underbakke</surname><given-names>E. S.</given-names></name>; <name><surname>Potter</surname><given-names>C. S.</given-names></name>; <name><surname>Carragher</surname><given-names>B.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name> (<year>2014</year>) <article-title>Single-particle
EM reveals the higher-order domain
architecture of soluble guanylate cyclase</article-title>. <source>Proc.
Natl. Acad. Sci. U.S.A.</source>
<volume>111</volume>, <fpage>2960</fpage>â<lpage>2965</lpage>.<pub-id pub-id-type="pmid">24516165</pub-id></mixed-citation>
      </ref>
      <ref id="ref22">
        <mixed-citation publication-type="journal" id="cit22"><name><surname>Winger</surname><given-names>J. A.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name> (<year>2005</year>) <article-title>Expression and characterization of the catalytic domains
of soluble guanylate cyclase: Interaction with the heme domain</article-title>. <source>Biochemistry</source>
<volume>44</volume>, <fpage>4083</fpage>â<lpage>4090</lpage>.<pub-id pub-id-type="pmid">15751985</pub-id></mixed-citation>
      </ref>
      <ref id="ref23">
        <mixed-citation publication-type="journal" id="cit23"><name><surname>Underbakke</surname><given-names>E. S.</given-names></name>; <name><surname>Iavarone</surname><given-names>A. T.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name> (<year>2013</year>) <article-title>Higher-order interactions bridge
the nitric oxide receptor and catalytic domains of soluble guanylate
cyclase</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>110</volume>, <fpage>6777</fpage>â<lpage>6782</lpage>.<pub-id pub-id-type="pmid">23572573</pub-id></mixed-citation>
      </ref>
      <ref id="ref24">
        <mixed-citation publication-type="journal" id="cit24"><name><surname>Rothkegel</surname><given-names>C.</given-names></name>; <name><surname>Schmidt</surname><given-names>P. M.</given-names></name>; <name><surname>Atkins</surname><given-names>D. J.</given-names></name>; <name><surname>Hoffmann</surname><given-names>L. S.</given-names></name>; <name><surname>Schmidt</surname><given-names>H. H.</given-names></name>; <name><surname>Schroder</surname><given-names>H.</given-names></name>; <name><surname>Stasch</surname><given-names>J. P.</given-names></name> (<year>2007</year>) <article-title>Dimerization
region of soluble guanylate
cyclase characterized by bimolecular fluorescence complementation
in vivo</article-title>. <source>Mol. Pharmacol.</source>
<volume>72</volume>, <fpage>1181</fpage>â<lpage>1190</lpage>.<pub-id pub-id-type="pmid">17715400</pub-id></mixed-citation>
      </ref>
      <ref id="ref25">
        <mixed-citation publication-type="journal" id="cit25"><name><surname>Busker</surname><given-names>M.</given-names></name>; <name><surname>Neidhardt</surname><given-names>I.</given-names></name>; <name><surname>Behrends</surname><given-names>S.</given-names></name> (<year>2013</year>) <article-title>Nitric Oxide Activation
of Guanylate
Cyclase Pushes the Î±<sub>1</sub> Signaling Helix and the Î²<sub>1</sub> Heme-binding Domain closer to the Substrate-binding Site</article-title>. <source>J. Biol. Chem.</source>
<volume>289</volume>, <fpage>476</fpage>â<lpage>484</lpage>.<pub-id pub-id-type="pmid">24220034</pub-id></mixed-citation>
      </ref>
      <ref id="ref26">
        <mixed-citation publication-type="journal" id="cit26"><name><surname>Fritz</surname><given-names>B. G.</given-names></name>; <name><surname>Roberts</surname><given-names>S. A.</given-names></name>; <name><surname>Ahmed</surname><given-names>A.</given-names></name>; <name><surname>Breci</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Weichsel</surname><given-names>A.</given-names></name>; <name><surname>Brailey</surname><given-names>J. L.</given-names></name>; <name><surname>Wysocki</surname><given-names>V. H.</given-names></name>; <name><surname>Tama</surname><given-names>F.</given-names></name>; <name><surname>Montfort</surname><given-names>W. R.</given-names></name> (<year>2013</year>) <article-title>Molecular Model of a Soluble Guanylyl Cyclase Fragment
Determined by Small-Angle X-ray Scattering and Chemical Cross-Linking</article-title>. <source>Biochemistry</source>
<volume>52</volume>, <fpage>1568</fpage>â<lpage>1582</lpage>.<pub-id pub-id-type="pmid">23363317</pub-id></mixed-citation>
      </ref>
      <ref id="ref27">
        <mixed-citation publication-type="journal" id="cit27"><name><surname>Purohit</surname><given-names>R.</given-names></name>; <name><surname>Fritz</surname><given-names>B. G.</given-names></name>; <name><surname>The</surname><given-names>J.</given-names></name>; <name><surname>Issaian</surname><given-names>A.</given-names></name>; <name><surname>Weichsel</surname><given-names>A.</given-names></name>; <name><surname>David</surname><given-names>C. L.</given-names></name>; <name><surname>Campbell</surname><given-names>E. V.</given-names></name>; <name><surname>Hausrath</surname><given-names>A. C.</given-names></name>; <name><surname>Rassouli-Taylor</surname><given-names>L.</given-names></name>; <name><surname>Garcin</surname><given-names>E. D.</given-names></name>; <name><surname>Gage</surname><given-names>M. J.</given-names></name>; <name><surname>Montfort</surname><given-names>W. R.</given-names></name> (<year>2014</year>) <article-title>YC-1 binding to
the Î² subunit of soluble guanylyl cyclase overcomes allosteric
inhibition by the Î± subunit</article-title>. <source>Biochemistry</source>
<volume>53</volume>, <fpage>101</fpage>â<lpage>114</lpage>.<pub-id pub-id-type="pmid">24328155</pub-id></mixed-citation>
      </ref>
      <ref id="ref28">
        <mixed-citation publication-type="book" id="cit28"><person-group person-group-type="allauthors"><name><surname>Leslie</surname><given-names>A. G. W.</given-names></name>, and <name><surname>Powell</surname><given-names>H. R.</given-names></name></person-group> (<year>2007</year>) <article-title>Processing diffraction data with
mosflm</article-title>. In <source>Evolving Methods for Macromolecular
Crystallography</source> (<person-group person-group-type="editor"><name><surname>Read</surname><given-names>R. J.</given-names></name>,
and <name><surname>Sussman</surname><given-names>J. L.</given-names></name></person-group>, Eds.) pp <fpage>41</fpage>â<lpage>51</lpage>, <publisher-name>Springer</publisher-name>, <publisher-loc>Dordrecht,
The Netherlands</publisher-loc>.</mixed-citation>
      </ref>
      <ref id="ref29">
        <mixed-citation publication-type="journal" id="cit29"><name><surname>McCoy</surname><given-names>A. J.</given-names></name>; <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>; <name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Winn</surname><given-names>M. D.</given-names></name>; <name><surname>Storoni</surname><given-names>L. C.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name> (<year>2007</year>) <article-title>Phaser crystallographic software</article-title>. <source>J. Appl. Crystallogr.</source>
<volume>40</volume>, <fpage>658</fpage>â<lpage>674</lpage>.<pub-id pub-id-type="pmid">19461840</pub-id></mixed-citation>
      </ref>
      <ref id="ref30">
        <mixed-citation publication-type="journal" id="cit30"><name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>; <name><surname>Hung</surname><given-names>L. W.</given-names></name>; <name><surname>Ioerger</surname><given-names>T. R.</given-names></name>; <name><surname>McCoy</surname><given-names>A. J.</given-names></name>; <name><surname>Moriarty</surname><given-names>N. W.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name>; <name><surname>Sacchettini</surname><given-names>J. C.</given-names></name>; <name><surname>Sauter</surname><given-names>N. K.</given-names></name>; <name><surname>Terwilliger</surname><given-names>T. C.</given-names></name> (<year>2002</year>) <article-title>PHENIX: Building new software for
automated crystallographic structure determination</article-title>. <source>Acta Crystallogr.</source>
<volume>D58</volume>, <fpage>1948</fpage>â<lpage>1954</lpage>.</mixed-citation>
      </ref>
      <ref id="ref31">
        <mixed-citation publication-type="journal" id="cit31"><name><surname>Emsley</surname><given-names>P.</given-names></name>; <name><surname>Cowtan</surname><given-names>K.</given-names></name> (<year>2004</year>) <article-title>Coot: Model-building tools for molecular graphics</article-title>. <source>Acta Crystallogr.</source>
<volume>D60</volume>, <fpage>2126</fpage>â<lpage>2132</lpage>.</mixed-citation>
      </ref>
      <ref id="ref32">
        <mixed-citation publication-type="journal" id="cit32"><name><surname>Zhou</surname><given-names>M.</given-names></name>; <name><surname>Dagan</surname><given-names>S.</given-names></name>; <name><surname>Wysocki</surname><given-names>V.</given-names></name> (<year>2012</year>) <article-title>Protein subunits released by surface
collisions of noncovalent complexes: Nativelike compact structures
revealed by ion mobility mass spectrometry</article-title>. <source>Angew. Chem., Int. Ed.</source>
<volume>51</volume>, <fpage>4336</fpage>â<lpage>4339</lpage>.</mixed-citation>
      </ref>
      <ref id="ref33">
        <mixed-citation publication-type="journal" id="cit33"><name><surname>Galhena</surname><given-names>A.</given-names></name>; <name><surname>Dagan</surname><given-names>S.</given-names></name>; <name><surname>Jones</surname><given-names>C.</given-names></name>; <name><surname>Beardsley</surname><given-names>R.</given-names></name>; <name><surname>Wysocki</surname><given-names>V.</given-names></name> (<year>2008</year>) <article-title>Surface-induced dissociation of peptides and protein
complexes in a quadrupole/time-of-flight mass spectrometer</article-title>. <source>Anal. Chem.</source>
<volume>80</volume>, <fpage>1425</fpage>â<lpage>1436</lpage>.<pub-id pub-id-type="pmid">18247517</pub-id></mixed-citation>
      </ref>
      <ref id="ref34">
        <mixed-citation publication-type="journal" id="cit34"><name><surname>Tesmer</surname><given-names>J. J.</given-names></name>; <name><surname>Sunahara</surname><given-names>R. K.</given-names></name>; <name><surname>Johnson</surname><given-names>R. A.</given-names></name>; <name><surname>Gosselin</surname><given-names>G.</given-names></name>; <name><surname>Gilman</surname><given-names>A. G.</given-names></name>; <name><surname>Sprang</surname><given-names>S. R.</given-names></name> (<year>1999</year>) <article-title>Two-metal-Ion catalysis in adenylyl cyclase</article-title>. <source>Science</source>
<volume>285</volume>, <fpage>756</fpage>â<lpage>60</lpage>.<pub-id pub-id-type="pmid">10427002</pub-id></mixed-citation>
      </ref>
      <ref id="ref35">
        <mixed-citation publication-type="journal" id="cit35"><name><surname>Haase</surname><given-names>T.</given-names></name>; <name><surname>Haase</surname><given-names>N.</given-names></name>; <name><surname>Kraehling</surname><given-names>J. R.</given-names></name>; <name><surname>Behrends</surname><given-names>S.</given-names></name> (<year>2010</year>) <article-title>Fluorescent Fusion
Proteins of Soluble Guanylyl Cyclase Indicate Proximity of the Heme
Nitric Oxide Domain and Catalytic Domain</article-title>. <source>PLoS
One</source>
<volume>5</volume>, <fpage>e11617</fpage>.<pub-id pub-id-type="pmid">20657650</pub-id></mixed-citation>
      </ref>
      <ref id="ref36">
        <mixed-citation publication-type="journal" id="cit36"><name><surname>Yuen</surname><given-names>P. S.</given-names></name>; <name><surname>Doolittle</surname><given-names>L. K.</given-names></name>; <name><surname>Garbers</surname><given-names>D. L.</given-names></name> (<year>1994</year>) <article-title>Dominant negative mutants of nitric
oxide-sensitive guanylyl cyclase</article-title>. <source>J. Biol. Chem.</source>
<volume>269</volume>, <fpage>791</fpage>â<lpage>793</lpage>.<pub-id pub-id-type="pmid">7904602</pub-id></mixed-citation>
      </ref>
      <ref id="ref37">
        <mixed-citation publication-type="journal" id="cit37"><name><surname>Lamothe</surname><given-names>M.</given-names></name>; <name><surname>Chang</surname><given-names>F. J.</given-names></name>; <name><surname>Balashova</surname><given-names>N.</given-names></name>; <name><surname>Shirokov</surname><given-names>R.</given-names></name>; <name><surname>Beuve</surname><given-names>A.</given-names></name> (<year>2004</year>) <article-title>Functional
characterization of nitric oxide and YC-1 activation of soluble guanylyl
cyclase: Structural implication for the YC-1 binding site?</article-title>. <source>Biochemistry</source>
<volume>43</volume>, <fpage>3039</fpage>â<lpage>3048</lpage>.<pub-id pub-id-type="pmid">15023055</pub-id></mixed-citation>
      </ref>
      <ref id="ref38">
        <mixed-citation publication-type="journal" id="cit38"><name><surname>Hatley</surname><given-names>M. E.</given-names></name> (<year>2000</year>) <article-title>Isolation
and Characterization of Constitutively Active Mutants of Mammalian
Adenylyl Cyclase</article-title>. <source>J. Biol. Chem.</source>
<volume>275</volume>, <fpage>38626</fpage>â<lpage>38632</lpage>.<pub-id pub-id-type="pmid">10982815</pub-id></mixed-citation>
      </ref>
      <ref id="ref39">
        <mixed-citation publication-type="journal" id="cit39"><name><surname>Tang</surname><given-names>W.-J.</given-names></name>; <name><surname>Stanzel</surname><given-names>M.</given-names></name>; <name><surname>Gilman</surname><given-names>A. G.</given-names></name> (<year>1995</year>) <article-title>Truncation
and Alanine-Scanning Mutants
of Type I Adenylyl Cyclase</article-title>. <source>Biochemistry</source>
<volume>34</volume>, <fpage>14563</fpage>â<lpage>14572</lpage>.<pub-id pub-id-type="pmid">7578062</pub-id></mixed-citation>
      </ref>
      <ref id="ref40">
        <mixed-citation publication-type="journal" id="cit40"><name><surname>Friebe</surname><given-names>A.</given-names></name>; <name><surname>Russwurm</surname><given-names>M.</given-names></name>; <name><surname>Mergia</surname><given-names>E.</given-names></name>; <name><surname>Koesling</surname><given-names>D.</given-names></name> (<year>1999</year>) <article-title>A Point-Mutated Guanylyl
Cyclase with Features of the YC-1-Stimulated Enzyme: Implications
for the YC-1 Binding Site?</article-title>. <source>Biochemistry</source>
<volume>38</volume>, <fpage>15253</fpage>â<lpage>15257</lpage>.<pub-id pub-id-type="pmid">10563809</pub-id></mixed-citation>
      </ref>
      <ref id="ref41">
        <mixed-citation publication-type="journal" id="cit41"><name><surname>Gregoret</surname><given-names>L. M.</given-names></name>; <name><surname>Rader</surname><given-names>S. D.</given-names></name>; <name><surname>Fletterick</surname><given-names>R. J.</given-names></name>; <name><surname>Cohen</surname><given-names>F. E.</given-names></name> (<year>1991</year>) <article-title>Hydrogen bonds involving
sulfur atoms in proteins</article-title>. <source>Proteins: Struct.,
Funct., Genet.</source>
<volume>9</volume>, <fpage>99</fpage>â<lpage>107</lpage>.<pub-id pub-id-type="pmid">1755867</pub-id></mixed-citation>
      </ref>
      <ref id="ref42">
        <mixed-citation publication-type="journal" id="cit42"><name><surname>Koglin</surname><given-names>M.</given-names></name>; <name><surname>Behrends</surname><given-names>S.</given-names></name> (<year>2004</year>) <article-title>Native human nitric
oxide sensitive guanylyl cyclase:
Purification and characterization</article-title>. <source>Biochem.
Pharmacol.</source>
<volume>67</volume>, <fpage>1579</fpage>â<lpage>1585</lpage>.<pub-id pub-id-type="pmid">15041475</pub-id></mixed-citation>
      </ref>
      <ref id="ref43">
        <mixed-citation publication-type="journal" id="cit43"><name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Feng</surname><given-names>C.</given-names></name>; <name><surname>Hazzard</surname><given-names>J. T.</given-names></name>; <name><surname>Tollin</surname><given-names>G.</given-names></name>; <name><surname>Montfort</surname><given-names>W. R.</given-names></name> (<year>2008</year>) <article-title>Binding
of YC-1 or BAY 41-2272 to Soluble Guanylyl Cyclase Induces a Geminate
Phase in CO Photolysis</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>130</volume>, <fpage>15748</fpage>â<lpage>15749</lpage>.<pub-id pub-id-type="pmid">18980304</pub-id></mixed-citation>
      </ref>
      <ref id="ref44">
        <mixed-citation publication-type="journal" id="cit44"><name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Murata</surname><given-names>L. B.</given-names></name>; <name><surname>Weichsel</surname><given-names>A.</given-names></name>; <name><surname>Brailey</surname><given-names>J. L.</given-names></name>; <name><surname>Roberts</surname><given-names>S. A.</given-names></name>; <name><surname>Nighorn</surname><given-names>A.</given-names></name>; <name><surname>Montfort</surname><given-names>W. R.</given-names></name> (<year>2008</year>) <article-title>Allostery
in recombinant soluble
guanylyl cyclase from <italic>Manduca sexta</italic></article-title>. <source>J. Biol. Chem.</source>
<volume>283</volume>, <fpage>20968</fpage>â<lpage>20977</lpage>.<pub-id pub-id-type="pmid">18515359</pub-id></mixed-citation>
      </ref>
      <ref id="ref45">
        <mixed-citation publication-type="journal" id="cit45"><name><surname>Denninger</surname><given-names>J. W.</given-names></name>; <name><surname>Schelvis</surname><given-names>J. P.</given-names></name>; <name><surname>Brandish</surname><given-names>P. E.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Babcock</surname><given-names>G. T.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name> (<year>2000</year>) <article-title>Interaction of soluble
guanylate cyclase with YC-1:
Kinetic and resonance Raman studies</article-title>. <source>Biochemistry</source>
<volume>39</volume>, <fpage>4191</fpage>â<lpage>4198</lpage>.<pub-id pub-id-type="pmid">10747811</pub-id></mixed-citation>
      </ref>
      <ref id="ref46">
        <mixed-citation publication-type="journal" id="cit46"><name><surname>Derbyshire</surname><given-names>E. R.</given-names></name>; <name><surname>Fernhoff</surname><given-names>N. B.</given-names></name>; <name><surname>Deng</surname><given-names>S.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name> (<year>2009</year>) <article-title>Nucleotide Regulation
of Soluble Guanylate Cyclase Substrate Specificity</article-title>. <source>Biochemistry</source>
<volume>48</volume>, <fpage>7519</fpage>â<lpage>7524</lpage>.<pub-id pub-id-type="pmid">19527054</pub-id></mixed-citation>
      </ref>
      <ref id="ref47">
        <mixed-citation publication-type="journal" id="cit47"><name><surname>Sharina</surname><given-names>I. G.</given-names></name>; <name><surname>Jelen</surname><given-names>F.</given-names></name>; <name><surname>Bogatenkova</surname><given-names>E. P.</given-names></name>; <name><surname>Thomas</surname><given-names>A.</given-names></name>; <name><surname>Martin</surname><given-names>E.</given-names></name>; <name><surname>Murad</surname><given-names>F.</given-names></name> (<year>2008</year>) <article-title>Î±1 Soluble Guanylyl Cyclase (sGC) Splice Forms as Potential
Regulators of Human sGC Activity</article-title>. <source>J. Biol. Chem.</source>
<volume>283</volume>, <fpage>15104</fpage>â<lpage>15113</lpage>.<pub-id pub-id-type="pmid">18381288</pub-id></mixed-citation>
      </ref>
      <ref id="ref48">
        <mixed-citation publication-type="journal" id="cit48"><name><surname>Yoo</surname><given-names>B.-K.</given-names></name>; <name><surname>Lamarre</surname><given-names>I.</given-names></name>; <name><surname>Rappaport</surname><given-names>F.</given-names></name>; <name><surname>Nioche</surname><given-names>P.</given-names></name>; <name><surname>Raman</surname><given-names>C. S.</given-names></name>; <name><surname>Martin</surname><given-names>J.-L.</given-names></name>; <name><surname>Negrerie</surname><given-names>M.</given-names></name> (<year>2012</year>) <article-title>Picosecond
to Second Dynamics Reveals
a Structural Transition in <italic>Clostridium botulinum</italic> NO-Sensor Triggered by the Activator BAY-41-2272</article-title>. <source>ACS Chem. Biol.</source>
<volume>7</volume>, <fpage>2046</fpage>â<lpage>2054</lpage>.<pub-id pub-id-type="pmid">23009307</pub-id></mixed-citation>
      </ref>
      <ref id="ref49">
        <mixed-citation publication-type="journal" id="cit49"><name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Pal</surname><given-names>B.</given-names></name>; <name><surname>Takenaka</surname><given-names>S.</given-names></name>; <name><surname>Tsuyama</surname><given-names>S.</given-names></name>; <name><surname>Kitagawa</surname><given-names>T.</given-names></name> (<year>2005</year>) <article-title>Resonance Raman Evidence
for the Presence of Two Heme Pocket Conformations with Varied Activities
in CO-Bound Bovine Soluble Guanylate Cyclase and Their Conversion</article-title>. <source>Biochemistry</source>
<volume>44</volume>, <fpage>939</fpage>â<lpage>946</lpage>.<pub-id pub-id-type="pmid">15654750</pub-id></mixed-citation>
      </ref>
      <ref id="ref50">
        <mixed-citation publication-type="journal" id="cit50"><name><surname>Slabinski</surname><given-names>L.</given-names></name>; <name><surname>Jaroszewski</surname><given-names>L.</given-names></name>; <name><surname>Rychlewski</surname><given-names>L.</given-names></name>; <name><surname>Wilson</surname><given-names>I. A.</given-names></name>; <name><surname>Lesley</surname><given-names>S. A.</given-names></name>; <name><surname>Godzik</surname><given-names>A.</given-names></name> (<year>2007</year>) <article-title>XtalPred: A web server for prediction of protein crystallizability</article-title>. <source>Bioinformatics</source>
<volume>23</volume>, <fpage>3403</fpage>â<lpage>3405</lpage>.<pub-id pub-id-type="pmid">17921170</pub-id></mixed-citation>
      </ref>
      <ref id="ref51">
        <mixed-citation publication-type="journal" id="cit51"><name><surname>Zhou</surname><given-names>M.</given-names></name>; <name><surname>Jones</surname><given-names>C. M.</given-names></name>; <name><surname>Wysocki</surname><given-names>V. H.</given-names></name> (<year>2013</year>) <article-title>Dissecting the Large Noncovalent
Protein Complex GroEL with Surface-Induced Dissociation and Ion MobilityâMass
Spectrometry</article-title>. <source>Anal. Chem.</source>
<volume>85</volume>, <fpage>8262</fpage>â<lpage>8267</lpage>.<pub-id pub-id-type="pmid">23855733</pub-id></mixed-citation>
      </ref>
      <ref id="ref52">
        <mixed-citation publication-type="journal" id="cit52"><name><surname>Zabel</surname><given-names>U.</given-names></name>; <name><surname>Hausler</surname><given-names>C.</given-names></name>; <name><surname>Weeger</surname><given-names>M.</given-names></name>; <name><surname>Schmidt</surname><given-names>H. H.</given-names></name> (<year>1999</year>) <article-title>Homodimerization
of soluble guanylyl cyclase subunits. Dimerization analysis using
a glutathione S-transferase affinity tag</article-title>. <source>J.
Biol. Chem.</source>
<volume>274</volume>, <fpage>18149</fpage>â<lpage>18152</lpage>.<pub-id pub-id-type="pmid">10373411</pub-id></mixed-citation>
      </ref>
      <ref id="ref53">
        <mixed-citation publication-type="journal" id="cit53"><name><surname>Wagner</surname><given-names>C.</given-names></name>; <name><surname>Russwurm</surname><given-names>M.</given-names></name>; <name><surname>Jager</surname><given-names>R.</given-names></name>; <name><surname>Friebe</surname><given-names>A.</given-names></name>; <name><surname>Koesling</surname><given-names>D.</given-names></name> (<year>2005</year>) <article-title>Dimerization
of nitric oxide-sensitive guanylyl cyclase requires the Î±1 N
terminus</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>17687</fpage>â<lpage>17693</lpage>.<pub-id pub-id-type="pmid">15749699</pub-id></mixed-citation>
      </ref>
      <ref id="ref54">
        <mixed-citation publication-type="journal" id="cit54"><name><surname>Shiga</surname><given-names>T.</given-names></name>; <name><surname>Suzuki</surname><given-names>N.</given-names></name> (<year>2005</year>) <article-title>Amphipathic Î±-helix
mediates the heterodimerization
of soluble guanylyl cyclase</article-title>. <source>Zool. Sci.</source>
<volume>22</volume>, <fpage>735</fpage>â<lpage>742</lpage>.<pub-id pub-id-type="pmid">16082162</pub-id></mixed-citation>
      </ref>
      <ref id="ref55">
        <mixed-citation publication-type="journal" id="cit55"><name><surname>Wedel</surname><given-names>B.</given-names></name>; <name><surname>Harteneck</surname><given-names>C.</given-names></name>; <name><surname>Foerster</surname><given-names>J.</given-names></name>; <name><surname>Friebe</surname><given-names>A.</given-names></name>; <name><surname>Schultz</surname><given-names>G.</given-names></name>; <name><surname>Koesling</surname><given-names>D.</given-names></name> (<year>1995</year>) <article-title>Functional
domains of soluble guanylyl cyclase</article-title>. <source>J. Biol.
Chem.</source>
<volume>270</volume>, <fpage>24871</fpage>â<lpage>24875</lpage>.<pub-id pub-id-type="pmid">7559610</pub-id></mixed-citation>
      </ref>
      <ref id="ref56">
        <mixed-citation publication-type="journal" id="cit56"><name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Gross</surname><given-names>S.</given-names></name>; <name><surname>Roussos</surname><given-names>C.</given-names></name>; <name><surname>Meurer</surname><given-names>S.</given-names></name>; <name><surname>Muller-Esterl</surname><given-names>W.</given-names></name>; <name><surname>Papapetropoulos</surname><given-names>A.</given-names></name> (<year>2004</year>) <article-title>Structural
and functional characterization of the dimerization
region of soluble guanylyl cyclase</article-title>. <source>J. Biol.
Chem.</source>
<volume>279</volume>, <fpage>24935</fpage>â<lpage>24943</lpage>.<pub-id pub-id-type="pmid">15037620</pub-id></mixed-citation>
      </ref>
      <ref id="ref57">
        <mixed-citation publication-type="journal" id="cit57"><name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Beuve</surname><given-names>A.</given-names></name>; <name><surname>van den
Akker</surname><given-names>F.</given-names></name> (<year>2010</year>) <article-title>Crystal structure of the signaling
helix coiled-coil domain of the Î²1 subunit of the soluble guanylyl
cyclase</article-title>. <source>BMC Struct. Biol.</source>
<volume>10</volume>, <fpage>2</fpage>.<pub-id pub-id-type="pmid">20105301</pub-id></mixed-citation>
      </ref>
      <ref id="ref58">
        <mixed-citation publication-type="journal" id="cit58"><name><surname>Sharina</surname><given-names>I.</given-names></name>; <name><surname>Sobolevsky</surname><given-names>M.</given-names></name>; <name><surname>Doursout</surname><given-names>M.-F.</given-names></name>; <name><surname>Gryko</surname><given-names>D.</given-names></name>; <name><surname>Martin</surname><given-names>E.</given-names></name> (<year>2011</year>) <article-title>Cobinamides
Are Novel Coactivators of Nitric Oxide Receptor That Target Soluble
Guanylyl Cyclase Catalytic Domain</article-title>. <source>J. Pharmacol.
Exp. Ther.</source>
<volume>340</volume>, <fpage>723</fpage>â<lpage>732</lpage>.<pub-id pub-id-type="pmid">22171090</pub-id></mixed-citation>
      </ref>
      <ref id="ref59">
        <mixed-citation publication-type="journal" id="cit59"><name><surname>Harding</surname><given-names>M.
M.</given-names></name> (<year>1999</year>) <article-title>The geometry
of metal-ligand interactions relevant to proteins</article-title>. <source>Acta Crystallogr.</source>
<volume>D55</volume>, <fpage>1432</fpage>â<lpage>1443</lpage>.</mixed-citation>
      </ref>
      <ref id="ref60">
        <mixed-citation publication-type="journal" id="cit60"><name><surname>Yang</surname><given-names>W.</given-names></name>; <name><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name><surname>Nowotny</surname><given-names>M.</given-names></name> (<year>2006</year>) <article-title>Making and Breaking Nucleic Acids:
Two-Mg<sup>2+</sup>-Ion Catalysis and Substrate Specificity</article-title>. <source>Mol. Cell</source>
<volume>22</volume>, <fpage>5</fpage>â<lpage>13</lpage>.<pub-id pub-id-type="pmid">16600865</pub-id></mixed-citation>
      </ref>
      <ref id="ref61">
        <mixed-citation publication-type="journal" id="cit61"><name><surname>Tabor</surname><given-names>S.</given-names></name>; <name><surname>Richardson</surname><given-names>C. C.</given-names></name> (<year>1989</year>) <article-title>Effect of manganese ions on the incorporation of dideoxynucleotides
by bacteriophage T7 DNA polymerase and <italic>Escherichia
coli</italic> DNA polymerase I</article-title>. <source>Proc.
Natl. Acad. Sci. U.S.A.</source>
<volume>86</volume>, <fpage>4076</fpage>â<lpage>4080</lpage>.<pub-id pub-id-type="pmid">2657738</pub-id></mixed-citation>
      </ref>
      <ref id="ref62">
        <mixed-citation publication-type="journal" id="cit62"><name><surname>Hoenicka</surname><given-names>M.</given-names></name>; <name><surname>Becker</surname><given-names>M.</given-names></name>; <name><surname>Apeler</surname><given-names>H.</given-names></name>; <name><surname>Sirichoke</surname><given-names>T.</given-names></name>; <name><surname>Schroder</surname><given-names>H.</given-names></name>; <name><surname>Gerzer</surname><given-names>R.</given-names></name>; <name><surname>Stasch</surname><given-names>J. P.</given-names></name> (<year>1999</year>) <article-title>Purified soluble
guanylyl cyclase expressed in a baculovirus/Sf9 system: Stimulation
by YC-1, nitric oxide, and carbon monoxide</article-title>. <source>J. Mol. Med.</source>
<volume>77</volume>, <fpage>14</fpage>â<lpage>23</lpage>.<pub-id pub-id-type="pmid">9930922</pub-id></mixed-citation>
      </ref>
      <ref id="ref63">
        <mixed-citation publication-type="journal" id="cit63"><name><surname>Beste</surname><given-names>K. Y.</given-names></name>; <name><surname>Burhenne</surname><given-names>H.</given-names></name>; <name><surname>Kaever</surname><given-names>V.</given-names></name>; <name><surname>Stasch</surname><given-names>J.-P.</given-names></name>; <name><surname>Seifert</surname><given-names>R.</given-names></name> (<year>2012</year>) <article-title>Nucleotidyl
Cyclase Activity of Soluble Guanylyl Cyclase Î±<sub>1</sub>Î²<sub>1</sub></article-title>. <source>Biochemistry</source>
<volume>51</volume>, <fpage>194</fpage>â<lpage>204</lpage>.<pub-id pub-id-type="pmid">22122229</pub-id></mixed-citation>
      </ref>
      <ref id="ref64">
        <mixed-citation publication-type="journal" id="cit64"><name><surname>Dove</surname><given-names>S.</given-names></name>; <name><surname>Danker</surname><given-names>K. Y.</given-names></name>; <name><surname>Stasch</surname><given-names>J.-P.</given-names></name>; <name><surname>Kaever</surname><given-names>V.</given-names></name>; <name><surname>Seifert</surname><given-names>R.</given-names></name> (<year>2014</year>) <article-title>Structure/Activity
Relationships of (M)ANT- and TNP-Nucleotides for Inhibition of Rat
Soluble Guanylyl Cyclase Î±<sub>1</sub>Î²<sub>1</sub></article-title>. <source>Mol. Pharmacol.</source>
<volume>85</volume>, <fpage>598</fpage>â<lpage>607</lpage>.<pub-id pub-id-type="pmid">24470063</pub-id></mixed-citation>
      </ref>
      <ref id="ref65">
        <mixed-citation publication-type="journal" id="cit65"><name><surname>Underbakke</surname><given-names>E. S.</given-names></name>; <name><surname>Iavarone</surname><given-names>A. T.</given-names></name>; <name><surname>Chalmers</surname><given-names>M. J.</given-names></name>; <name><surname>Pascal</surname><given-names>B. D.</given-names></name>; <name><surname>Novick</surname><given-names>S.</given-names></name>; <name><surname>Griffin</surname><given-names>P. R.</given-names></name>; <name><surname>Marletta</surname><given-names>M. A.</given-names></name> (<year>2014</year>) <article-title>Nitric Oxide-Induced Conformational
Changes in Soluble Guanylate Cyclase</article-title>. <source>Structure</source>
<fpage>DOI: 10.1016/j.str.2014.01.008</fpage>.</mixed-citation>
      </ref>
      <ref id="ref66">
        <mixed-citation publication-type="journal" id="cit66"><name><surname>Wilkins</surname><given-names>M. R.</given-names></name>; <name><surname>Lindskog</surname><given-names>I.</given-names></name>; <name><surname>Gasteiger</surname><given-names>E.</given-names></name>; <name><surname>Bairoch</surname><given-names>A.</given-names></name>; <name><surname>Sanchez</surname><given-names>J.-C.</given-names></name>; <name><surname>Hochstrasser</surname><given-names>D. F.</given-names></name>; <name><surname>Appel</surname><given-names>R. D.</given-names></name> (<year>1997</year>) <article-title>Detailed peptide characterization
using PEPTIDEMASS: A World-Wide-Web-accessible tool</article-title>. <source>Electrophoresis</source>
<volume>18</volume>, <fpage>403</fpage>â<lpage>408</lpage>.<pub-id pub-id-type="pmid">9150918</pub-id></mixed-citation>
      </ref>
      <ref id="ref67">
        <mixed-citation publication-type="journal" id="cit67"><name><surname>Arnold</surname><given-names>K.</given-names></name>; <name><surname>Bordoli</surname><given-names>L.</given-names></name>; <name><surname>Kopp</surname><given-names>J.</given-names></name>; <name><surname>Schwede</surname><given-names>T.</given-names></name> (<year>2006</year>) <article-title>The SWISS-MODEL
Workspace:
A web-based environment for protein structure homology modelling</article-title>. <source>Bioinformatics</source>
<volume>22</volume>, <fpage>195</fpage>â<lpage>201</lpage>.<pub-id pub-id-type="pmid">16301204</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>